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ABSTRACT 
EXPLORING THE ARCHITECTURE OF THE HUMAN GABAA  
RECEPTOR LIGAND BINDING POCKET VIA MUTATIONAL, 
ELECTROPHYSIOLOGICAL, AND KINETIC ANALYSIS 
 
 
Kurt Laha, B.S. 
 
Marquette University, 2011 
 
 
The γ-aminobutyric acid type A (GABAA) receptor is a member of the cys-loop 
family of ligand-gated ion channels, and plays a crucial role in normal brain function by 
providing inhibitory neurotransmission.  The objective of my research is to establish the 
mechanisms that underlie the interaction between the GABAA receptor and GABA during 
binding, as well as to provide direct information about the architecture of the ligand 
binding pocket.  To achieve this, a multitude of amino acid residues surrounding the 
GABA binding pocket were individually mutated and structure-function relationships 
were explored.  Changes in EC50-GABA, macroscopic kinetics, GABA binding rates and 
GABA unbinding rates were assessed using patch-clamp recording, rapid-ligand 
application, and kinetic modeling techniques.   
 
A state-dependent interaction bridging the β/α inter-subunit interface was 
identified between α1R120 and β2D163 by characterizing GABA binding and unbinding 
rates for alanine mutations at each residue.  These results were subjected to double-
mutant cycle analysis.  Intriguingly, the residues appear to be completely independent 
when considering the binding of GABA, but they are coupled when looking at the 
unbinding of GABA.  These results suggest that β2D163 and α1R120 do not interact in 
the unbound state but form an interaction upon binding of GABA.  
 
A role for β2F200 at the GABA binding site was also revealed.  Mutation of 
β2F200 to alanine caused a dramatic reduction in GABA affinity.  This was the result of 
both an increase in the rate of GABA unbinding and a decrease in the GABA binding 
rate.  β2F200 fits the profile of a residue that could directly interact with GABA.    
 
Finally, three mutations of the β2 subunit (Y97A, Y157A, and D163A) have 
interesting effects on the functional expression of receptors.  Mutation of these residues 
allowed the assembly of functional receptors when expressed with α1 and γ2, but not 
when expressed with α1 only.  The aligned residues on the γ2 subunit were also mutated 
and found to have unique expression patterns.  Each of the residues appears to be 
required for the assembly of the β(+)/β(-) interface, which is only present in αβ receptors; 
however, only the residue homologous to β2Y97 (γ2F112) is critical for assembly at the 
γ/β interface.  
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I.  Introduction 
This dissertation explores the structure and function of the γ-aminobutyric acid 
type A (GABAA) receptor.  The primary objective is to advance our understanding of 
ligand binding.  This dissertation provides new information about the architecture of the 
γ-aminobutyric acid (GABA) binding pocket and the interactions that exist between the 
ligand and receptor. 
The GABAA receptor is a member of the cys-loop family of ligand-gated ion 
channels (LGICs), including the nicotinic acetylcholine, serotonin-type 3, and glycine 
receptors.  It is found on nearly every neuron in the brain (Sieghart and Sperk, 2002) and 
it acts as the major inhibitory receptor of the central nervous system (Enna and Mohler, 
2007).  By providing inhibition of neuronal signaling, the GABAA receptor plays a 
crucial role in normal brain processing.  Therefore, the GABAA receptor has been a 
common target for therapeutic agents treating disorders that result from errant signaling, 
such as epilepsy and anxiety.   
Despite the important role and prevalence of GABAA receptors and other LGICs 
in the central nervous system, a detailed functional description of the structural elements 
that are responsible for ligand binding, channel gating, and receptor desensitization 
remains unresolved.  LGICs are dynamic, allosteric proteins that rely on complex 
networks of interactions within and between each subunit in order to carry out their 
functions.  Fascinating and most puzzling of all is how the binding of a neurotransmitter 
is able to provoke conformational changes that lead to the opening of an ion channel.  
This is a fundamental question in protein biology, but the structural underpinnings of this 
process in cys-loop LGICs have not been identified.  A comprehensive understanding of 
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the biomolecular function of LGICs requires knowledge of the atomic interactions 
between the receptor and its ligand, and the subsequent conformational changes that lead 
to channel activation.  This understanding begins with an accurate description of the 
ligand binding pocket. 
The findings presented in this dissertation refine the structural model of the 
GABA binding pocket, separate the functional contributions of specific residues in the 
GABA binding pocket, and shed light on molecular interactions between the receptor and 
ligand.  The specific aims were designed to study amino acid residues around the GABA
 
binding pocket, identifying those that directly interact with GABA and those that mediate 
inter/intra-subunit interactions that influence binding.  Site-directed mutagenesis and a 
variety of electrophysiology experiments were employed to investigate the structure-
function relationships associated with GABA binding pocket residues.    The results 
yielded a multitude of new evidence.  Thirteen residues believed to line the binding 
pocket were characterized for their influence on peak EC50 values, deactivation kinetics, 
and desensitization kinetics, allowing specific functional roles to be distinguished 
(Chapter III).  A residue (α1R120) that indirectly contributes to the structural integrity of 
the binding pocket by means of a state-dependent inter-subunit interaction was identified 
(Chapters IV and V).  Support for the precise location of GABA when bound came from 
the identification of a residue (β2F200) central to the binding of GABA, and evidence of 
an interaction between this residue and a nearby residue (β2R207) was found (Chapter 
VI).  Lastly, several residues with a critical role in assembly of the receptor oligomer 
were identified (β2Y97, β2Y157, β2D163) (Chapter VII).  Incorporation of these results 
into the current structural model clarifies the exact positioning of several structural 
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elements at the binding pocket and supports a precise orientation for GABA with the 
positive amino group located between β2F200 and β2Y97. 
The major inhibitory receptor of the central nervous system: GABAA 
 Gamma-aminobutyric acid (GABA) is the most abundant inhibitory 
neurotransmitter in the vertebrate central nervous system where it activates GABAA, 
GABAB, and GABAC receptors (Macdonald and Olsen, 1994).  The GABAA receptor is a 
member of the cys-loop LGICs that includes the nicotinic acetylcholine (nACh), 
serotonin type 3 (5-HT3), and glycine receptors; the GABAB receptor is a G-protein 
coupled receptor; and the GABAC receptor is a homomeric LGIC found primarily in the 
retina (Enz and Cutting, 1998) and is considered part of the GABAA receptor family.  
Similar in structure to other cys-loop LGICs, the GABAA receptor is comprised of five 
heterologous subunits arranged around a central ion-conducting channel, depicted in 
Figure 1.1 (Kash et al., 2004).  Each subunit has an amino-terminus half that forms an 
extra-cellular domain responsible for ligand binding, and a carboxy-terminus half 
containing four trans-membrane domains that form the ion-selective channel. 
 
Figure 1.1  The molecular structure of Cys-loop 
ligand-gated ion channels.  A) The cys-loop LGICs 
possess a large extracellular N-terminal domain 
containing the disulfide bond signature of the 
superfamily (*), followed by four transmembrane 
domains (shown by boxes).  Arrows identify the 
extracellular (EC) and the intracellular (IC) domains.  
B) Receptors are constructed as pentameric ion 
channels from the assembly of five subunits 
(numbered 1-5) in a ring structure, creating an ion 
pore within.  This image depicts an extracellular view 
from above the membrane, looking down at a 
receptor. 
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 The GABAA receptor plays an important role in brain function, for it is found on 
virtually every neuron in the brain and it acts as the major inhibitory receptor of the 
central nervous system (Enna and Mohler, 2007).  In general, LGICs mediate synaptic 
transmission and shape the flow of information in the brain, hence controlling both 
behavior and cognitive function (Connolly and Wafford, 2004).  They can provide 
excitatory or inhibitory potentials that alter the membrane potential of neurons, and 
thereby increase or decrease firing of action potentials and propagation of neuronal 
signaling.  The GABAA receptor contains a chloride channel and when activated, as by its 
endogenous ligand GABA, the receptor allows the conductance of chloride ions across 
the cell membrane.  In fully developed organisms this has an inhibitory effect as the 
negatively charged chloride ions flow down their electrochemical gradient and into the 
cell, making the inside of the cell more negative and less likely to fire an action potential.   
 As the major inhibitory channel of the central nervous system, the GABAA 
receptor is crucial for proper neuronal signaling.  It provides inhibition that is central to 
the regulation of neuronal excitability and the timing of synchronous population 
oscillations (Whittington et al., 1995; Whittington et al., 2000).  Both are critical to 
normal cognitive function.  The GABAA receptor is essential in reflex responses, 
voluntary motor control, and processing of sensory signaling (Enna and Mohler, 2007).  
Disruption of inhibitory pathways leads to aberrant brain activity and can result in 
epilepsy, loss of muscle control, anxiety, and sleep disorders.  Therapeutic agents for all 
of these disorders target the GABAA receptor (Johnston, 2005), and several GABAA 
receptor mutations predispose humans to idiopathic generalized epilepsy (Macdonald et 
al., 2010).   
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Figure 1.2  Agonists, antagonists, and modulators of the GABAA receptor.  The schematic 
representation of a GABAA receptor illustrates the different sites of action for each molecule.  
The agonist, GABA, and the antagonists, bicuculline and SR-95531 bind at both β/α inter-subunit 
interfaces.  Benzodiazepines bind at the α/γ inter-subunit interface (Sigel and Buhr, 1997; Boileau 
et al., 1998).  Propofol binds near the extracellular end of the third transmembrane domain on the 
β subunit (Bali and Akabas, 2004).  Pentobarbitol interacts with parts of the first three 
transmembrane domains of β subunits (Amin, 1999; Serafini et al., 2000).  Neurosteroids interact 
with the transmembrane domains at β/α inter-subunit interfaces and within a cavity of the α 
subunit (Hosie et al., 2006; Akk et al., 2008).  Volatile anesthetics and alcohols interact with the 
receptor at sites in the transmembrane domains (Mihic et al., 1997).   Zinc acts from within the 
ion pore at non-GABA binding α/β inter-subunit interfaces (Hosie et al., 2003).  Picrotoxin is an 
open channel blocker, interacting with transmembrane domains from within the ionopore (Xu et 
al., 1995). 
 
The relevance of the GABAA receptor in brain function is further illustrated by 
the fact that it is modulated by a multitude of compounds including anesthetics, Zn2+, 
ethanol, barbiturates, and benzodiazepines (Smith and Olsen, 1995).  These compounds 
have distinct binding sites located in numerous regions around the receptor.  Specific 
binding sites have been found at inter-subunit interfaces, in pockets within a subunit, at 
transmembrane domains, and inside the ion pore (Figure 1.2).  This rich pharmacology 
provides the impetus both for the identification of better therapeutic agents with which to 
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modulate receptor function, and also for the use of this protein as a model system to study 
complex interactions between ligands and receptors. 
GABAA receptor structural progress 
 A high resolution structure has yet to be determined for the GABAA receptor or 
any other cys-loop LGIC, limiting our ability to assess the precise interactions that 
underlie ligand binding.  Ideally, x-ray diffraction experiments would provide atomic-
resolution details of this interaction; however, the complexity of the membrane bound 
receptors with binding sites at subunit interfaces has made obtaining sufficient amounts 
of pure protein, and crystallization of these receptors for such experiments very difficult.  
The only crystallized structure of a LGIC is of the extracellular domain of a single 
subunit from the nACh receptor (Dellisanti et al., 2007).  It represents just a monomer of 
the pentameric protein and therefore does not form a functional ligand binding site.  
Some insights into the general structure of a complete nACh receptor have been provided 
by electron microscopy, but images are limited to a resolution of 4 angstroms (Miyazawa 
et al., 2003; Unwin, 2005).  Nevertheless, a wealth of structural information has come 
from cloning, heterologous expression, electrophysiology, mutagenesis, and homology 
modeling.   These studies have provided insight, although limited, as to how the structure 
of GABAA contributes to receptor function. 
Cloning of LGICs 
 The first LGIC subunit cloned was of the nAChR in 1982 (Noda et al., 1983).   
This solidified the existence of such ion channels, and allowed for the expression of the 
receptor in oocytes in order to perform electrophysiological experiments on a specific 
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channel.  In 1987, a cloning study by Eric Barnard and Peter Seeburg yielded the first 
GABAA receptor cDNA sequences (Schofield et al., 1987).  Cloning has since identified 
the amino acid sequences of 19 GABAA receptor subunit isoforms (Simon et al., 2004).  
Furthermore, comparison of cDNA sequences from GABAA, glycine, 5-HT3, and nACh 
receptor subunits indicates that all of them are structurally related, now known as 
members of the cys-loop LGIC superfamily because of two conserved extracellular 
cysteines that are capable of forming a disulfide bond and create a loop structure.  Figure 
1.3 depicts an alignment of the amino acid sequences of the extra-cellular domains of 
cys-loop LGIC subunits from each receptor type.  Although their primary sequences vary, 
they have conserved secondary structures and many absolutely conserved residues that 
serve as useful anchor points and allow for alignment.  These similarities justify 
modeling cys-loop LGICs together. 
The cloning of the LGIC sequences has enabled the prediction of their secondary 
structure and has guided structural studies aimed at understanding the ligand-receptor 
complex.  The identification of subunit sequences provided an early indication of the 
location of the GABA binding pocket.  Sigel et al. (1992) found that a point mutation in 
the rat α1 subunit (F64L) caused a strong decrease in agonist and antagonist affinity when 
expressed with β2 and γ2 in oocytes.  Sequence analysis has also supported the conserved 
existence of six loop structures that are believed to mediate ligand binding in all cys-loop 
LGICS, as highlighted in Figure 1.3 and shown in Figure 1.4 (Kash et al., 2004). 
 
 
 
 
  
 
  
 
Figure 1.3.  Cys-loop receptors share conserved secondary structures and can be 
modeled after the AChBP.
terminal domains of the α1, β
mouse serotonin type 3A receptor subunit, the 
the α1 subunit of the mouse nicotinic acetylcholine receptor, and the
acetylcholine binding protein (AChBP).  Light blue boxes signify predicted helices and 
light green boxes signify predicted 
Dellisanti et al., 2007).  The cysteine residues, which form the disulfide bond that is 
characteristic of all cys-loop receptors, are indicated by asterisks (*).  
primary sequences, these secondary structures align very well.  The six
site loops are labeled A-F (Kash et al., 2004) and contain a number of residues implicated 
in binding.  Underlined residues indicate those found to face into the binding pocket.  
Blue colored residues denote those previously implicated in
are the focus of the studies presented in this dissertation.
 
 
 
 
 
  Presented here is the alignment of the extracellular N
2, γ2, and ρ1 subunits of the human GABA
α1 subunit of the human glycine receptor, 
 Lymnaea stagnalis
β sheets (Brejck et al., 2001; O’Mara et al., 2
Despite variation in 
 putative binding 
 GABA binding and which 
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Assembly of the GABAA receptor
 Along with the advent of cloning, an understanding of the stoichiometry and 
assembly of GABAA receptors developed.  Work by Levitan et al. (1988), examining the 
structural basis behind variations 
GABAA receptors required both 
subunits and a β subunit were isolated.  This indicated that GABA
heterogeneous, being formed by combin
classes.  Furthermore, expression studies have confirmed that a heteromeric combination 
of both α and β subunits is necessary and sufficient for receptor function (Pritchett et al., 
1989), and eventual biochemical studies revealed that the GABA
pentameric stoichiometry (Chang et al., 1996; Tretter et al., 1997; Farrar et al., 1999).   A 
pentameric structure is also supported by the crystallized pentameric A
2001) and electron microscopy
2003). 
 
 
Figure 1.4  Six discontinuous loops 
support binding at subunit interfaces.
This schematic representation of the GABA
receptor demonstrates the unique 
contributions from the α subunit and 
subunit.  Note each subunit is asymmetric 
and therefore opposite sides of the 
and β subunit are involved in GABA 
binding.  The classic binding site loop 
nomenclature is used (Kash et al., 2004).
 
 
 
 
in receptor behavior, found functional expression of 
α and β subunit isoforms, and cDNAs encoding several 
A receptors are 
ations of different isoforms of several subunit 
A receptor has a 
ChBP (Brejc et al., 
 images of a pentameric nACh receptor (Miyazawa et al., 
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β 
α subunit 
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The five GABAA receptor subunits are arranged pseudo-symmetrically around a 
central ion-conducting channel.  Eight different subunit classes with 19 isoforms have 
been identified to date (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ).  As shown in Figure 1.1 each subunit 
has an extracellular amino-terminus domain and a carboxy-terminus domain containing 
four transmembrane domains with an intracellular loop between transmembrane domain 
3 and transmembrane domain 4.  Subunits are cotranslationally inserted into the 
membrane of the endoplasmic reticulum, after which they fold and oligomerize 
(Connolly et al., 1996; Griffon et al., 1999).  Properly folded and oligomerized GABAA 
receptors are transported to the cell surface, whereas misfolded or improperly 
oligomerized subunits are retained in the endoplasmic reticulum and degraded 
(Klausberger et al., 2001a).  
During these folding and oligomerization events, each subunit must recognize its 
neighbors via specific high-affinity interactions.  Selective discriminations must be made 
between different subunits to achieve the correct order of subunits around the pore.  The 
stoichiometry and arrangement of GABAA receptor subunits has been explored using 
biochemical, immunohistochemical, and electrophysiology methods, and is depicted in 
Figure 1.5.  Early evidence for the requirement of specific subunit combinations in 
GABAA receptors came from expression studies that found α and β subunit combinations 
or α, β, and γ subunit combinations could produce functional surface expression; 
however, expressing α or β alone, or combinations of α and γ or β and γ results in the 
accumulation of non-surface receptor combinations retained in the endoplasmic reticulum 
(Connolly et al., 1996).  Using western blots where the relative reactivity of the 
antibodies had been determined, the ratio of subunits in recombinant receptors comprised 
  
of α1β3 subunits or α1β3γ2 was found to be 2
al., 1997).  Additionally, the maximal fluorescent signal
when expressing α1(c-myc)β2
as intense with labeled α1(c-myc) or 
2:2:1 stoichiometry (Farrar et al., 1999).  
Furthermore, fluorescence energy transfer experiments with two separate 
fluorescently conjugated antibodies performed on 
receptors resulted in significant energy transfer, but when performed on 
receptors did not result in energy transfer (Farrar et al., 1999).  Assuming only labeled 
subunits within the same receptor are close enough for energy transfer to oc
result supports multiple α and multiple 
subunit.  Another confirmation of the 2:2:1 stoichiometry was provided using the 
expression of α-β and β-α concatenated subunits, which could not produce
receptors when expressed alone or with 
expression occurred (Baumann et al., 2001).  The use of a variety of concatenated subunit 
combinations also demonstrated that the only subunit arrangement
that successfully led to functional receptors trafficked to the cell surface was 
α1:3β3 and 2α1:2β3:1γ2, respectively (Tretter et 
, from c-myc labeled subunits 
γ2, α1β2(c-myc)γ2, and α1β2γ2(c-myc) receptors,
β2(c-myc) than with labeled γ2(c-myc), supporting a 
 
 
Figure 1.5  GABA
stoichiometry.  Depicted is a GABA
receptor composed of 2α
fifth subunit that is either 
These subunits have been shown to 
assemble with a clockwise orientation 
of α,β,α,β, and γ or 
endogenous agonist, GABA, binds at 
the β/α interfaces, indicated by black 
triangles. 
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β
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γ subunits 
2α1β2α1γ2 
12 
 
 
(Baumann et al., 2002) (Figure 1.5).  This subunit arrangement is consistent with the 
formation of the appropriate inter-subunit interfaces known to bind GABA (β/α 
interfaces) and benzodiazepines (γ/β interface) (Cromer et al., 2002).    
 The key to understanding receptor diversity is the identification of assembly 
signals that govern which subunits prefer to be positioned next to each other.  A region 
required for assembly of all GABAA receptor subunits was identified in the cytoplasmic 
loop between transmembrane domains 3 and 4 (Lo et al., 2008); however, the majority of 
assembly signals have been found in the N-terminal extracellular domain (Srinivasan et 
al., 1999; Klausberger et al., 2000; Taylor et al., 2000; Klausberger et al., 2001b; Sarto et 
al., 2002; Ehya et al., 2003; Bollan et al., 2003; Sarto-Jackson et al., 2006; Bracamontes 
and Steinbach, 2008).  Many of these signals lie at or near predicted subunit interfaces. 
The physiological impact of receptor assembly is also evident.  Mutations that 
alter surface expression of receptors from the cys-loop family of ligand-gated ion 
channels have been associated with idiopathic generalized epilepsies (Macdonald et al., 
2010), congenital myasthenic syndrome (Shen et al., 2005), and psychiatric disorders 
(Niesler et al., 2001).  Unfortunately because the structural and cellular determinants of 
receptor biogenesis are poorly understood, development of effective treatment strategies 
remains a significant challenge. 
Photoaffinity labeling used to locate the GABA binding site 
 Photoaffinity labeling experiments provided the first direct evidence for the 
location of the GABA binding site, and have confirmed the participation of both α and β 
subunits in the formation of the GABA binding site.  In two separate studies, the β 
subunit was identified as the major site of incorporation of the GABA homologue [3H] 
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muscimol (Casalotti et al., 1986; Deng et al., 1986).  In each, GABAA receptors were 
purified from mammalian brain by a benzodiazepine affinity column and photoaffinity 
labeled with [3H] muscimol.  SDS-PAGE and Western blotting revealed the label 
incorporated into a single broad band of 57 kDa corresponding to the β subunit.  
However, when higher concentrations of purified receptor protein were analyzed in the 
photoaffinity reaction, bands corresponding to both α (52kDa) and β (57kDa) subunits 
were labeled by [3H] muscimol.  Later, photoaffinity labeling of affinity purified bovine 
GABAA receptor with [3H] muscimol, followed by microsequencing of a chymotryptic 
fragment identified F65 on the α1 subunit as a residue associated with the ligand (Smith 
and Olsen, 1994).  This is the corresponding residue identified by Sigel et al. in 1992, 
strengthening its presumed involvement in ligand binding. 
Mutagenesis at the GABA binding pocket 
 Mutagenesis studies have identified several amino acid residues that may be 
involved in binding, all of which fall on or adjacent to the six discontinuous loops of the 
β/α inter-subunit interface. In general, a mutation that resulted in a large rightward shift 
of the GABA concentration-response curve indicated the residue has a possible role in 
binding.  Residues that were sensitive to mutation by this measure are denoted in Figure 
1.3 (highlighted blue).  Although a variety of expression systems, subunit isoforms, and 
side-chain substitutions were utilized in each study, the basic interpretation that a large 
effect on EC50 suggests a role in binding remains the same.   
Concentration-response curves are determined by microscopic processes of ligand 
binding/unbinding, channel opening/closing, and desensitization/resensitization.  
However, concentration-response curves do not directly reveal information about these 
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individual microscopic processes (Colquhuon, 1998).  Wagner et al. (2004) provided the 
first study to dissect the biophysical role a binding pocket residue plays in channel 
function.  They examined a cysteine mutation of β2R207 using rapid-ligand application, 
single-channel recording, and kinetic modeling. β2R207C caused a 20-fold increase in the 
unbinding rate of GABA, an eightfold decrease in the binding rate of GABA, and had no 
effect on any of the rates associated with gating.  They concluded β2R207 is important for 
stabilizing the ligand-receptor complex, and suggested that a direct interaction between 
the GABA molecule and β2R207 may occur. 
Each loop domain (shown in Figures 1.3 and 1.4) has also been probed using the 
substituted cysteine accessibility method (SCAM) in order to determine secondary 
structure and identify specific residues that face the ligand binding pocket (Boileau et al., 
1999; Wagner and Czajkowski, 2001; Boileau et al., 2002; Holden et al., 2002; Newell 
and Czajkowski, 2003; Newell et al., 2004; Kloda and Czajkowski, 2007).  SCAM 
evaluates residues mutated to cysteine for accessibility to reaction with a sulfhydryl 
reactive reagent, thereby indicating if the residue is found on the aqueous surface within 
or near the GABA binding site.  Residues found to be accessible to the sulfhydryl 
reactive reagent and hence potentially face the binding pocket are highlighted in Figure 
1.3.  For many of the residues on the six loops (when mutated to cysteine) no effect was 
observed during reaction with a sulfhydryl reagent.  The lack of an effect could arise if 
the mutated residue was not accessible and did not react with the reagent, or if reaction 
with the reagent did not interfere with receptor function. 
  
 As each loop was examined by SCAM, information about their secondary 
structure was revealed.  The alternating accessibility patterns of consecu
reaction with a sulfhydryl reagent observed for loops A and D is consistent with a beta
strand (Boileau et al., 1999; Boileau et al., 2002).  Loops B, C, F did not demonstrate 
accessibility patterns consistent with any regular secondary st
helix or a beta strand, and appear to be water
al., 2004; Wagner et al., 2001; Newell et al., 2003).  The accessibility pattern of loop E 
was consistent with short beta strands separated
Figure 1.6 Chemical structures of SR
Furthermore, SCAM experiments examining the rate of reaction in the presence 
of agonist or antagonist can indicate if a given residue lies near the ligand binding site.  
GABA and SR-95531 share a structural motif
separated by a three carbon chain
GABA for a number of these residues, increasing the likelihood of a direct interaction 
with GABA (Loop D: α1F65C, 
α1E123C, α1L128C, α1T130C, and 
Loop A: β2Y97C and β2L99C; Loop B: 
β2Y205C, β2R207, and β2S209).  Although reduced accessibility in the presence of a 
tive residues to 
ructure, such as an alpha 
-accessible random coils or turns (Newell et 
 by a loop structure (Kloda et al., 2007).  
-95531 and GABA 
 with a carboxy group and an amino group 
, depicted in Figure 1.6.  Accessibility was protected by 
α1R67C, and α1S69C; Loop E: α1K117C, α1L118C, 
α1R132; Loop F: α1V178C, α1V180C, and 
β2T160C and β2D163C; Loop C: β2S204C, 
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ligand can indicate proximity to the ligand binding site, it might also be caused by 
allosteric effects induced by ligand binding.  All of the aforementioned residues, except 
α1S69C, α1K117C, and α1E123C, were also protected by the competitive antagonist SR-
95531.  This supports proximity to the ligand binding site because SR-95531 does not 
induce gating or the same conformational changes (if any) as GABA.  The residues 
α1D63C and α1R120C were only protected from reaction by SR-95531, which is larger 
than GABA.  These residues must additionally be considered near the binding pocket, but 
not in as close proximity to GABA. 
The use of unnatural amino acid mutagenesis has also been used extensively to 
investigate residues at the binding sites of LGICs.  In vivo nonsense suppression methods 
allow synthetic amino acids to be incorporated during translation of a protein and provide 
a powerful tool to exploit the specific chemical properties of a side-chain.  The technique 
has been successfully applied in LGICs to explore cation-π interactions, which occur 
between a cation and the negative electrostatic potential on the face of an aromatic ring.  
Aromatic residues are clustered near the binding pockets of each LGIC receptor.  These 
residues may provide a hydrophobic region which occludes water from the binding 
pocket, as well as be a site of direct interaction with ligands.   
At least one aromatic residue in nACh receptors (Zhang et al., 1998), 5-HT3 
receptors (Beene et al., 2002), and GABAC receptors (Lummis et al., 2005) has been 
shown to participate in cation-π interactions at the binding pocket.  For the GABAA 
receptor several aromatic residues are close to the binding pocket, including Y97 (loop 
A), Y157 (loop B), F200 (loop C), Y205 (loop C), and F65 (loop D).  Padgett et al. 
(2007) explored the cation-π ability of Y97, Y157, and Y205 using unnatural amino acid 
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mutagenesis.  They were able to identify cation-π interactions by incorporation of 
fluorinated aromatics, which had a spectrum of cation-π binding ability.  This is because 
fluorine is electron-withdrawing, and each fluorine addition serves to further reduce the 
negative electrostatic potential on the face of the aromatic ring.  Only Y97 demonstrated 
a direct relationship between the decreased cation-π ability and the resulting change in 
EC50-GABA.  In fact, Y97 shows the steepest correlation of any cation-π residue identified 
in LGICs, and has been postulated to interact with the primary amine of GABA. 
Homology modeling 
 The crystallization of a related protein, the acetylcholine binding protein 
(AChBP), has provided enormous insight into the structure of the extra-cellular domain 
of LGICs.    The AChBP is a soluble protein found in the snail Lymnaea stagnalis.  It is a 
pentamer of identical subunits, each containing 210 amino acids.  It has only 24% 
sequence homology with the N-terminus of the human nAChR α1 subunit and lacks 
membrane crossing regions, the pore, and the large intra-cellular sequence.  Nevertheless,  
the binding site region shares a strong similarity to that of the nicotinic receptor, and the 
snail protein has been used as a guide to the extra-cellular structure of other cys-loop 
receptors.  Cys-loop LGICs are modeled together because they have a similar architecture 
as depicted in Figure 1.1: an amino-terminus extra-cellular domain, a cys-loop, 4 TMDs, 
and a pentameric structure surrounding an ion pore.  Although there is limited homology 
at the primary structural level, several residues are absolutely conserved in all members.  
Furthermore, structural analysis reveals similar secondary and tertiary structure.  The 
homology model extrapolated from the AChBP crystal structure correctly predicted that 
the ligand binding domain is formed at the interfaces between subunits, supporting its use 
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as a valid template for the extra-cellular domain of the GABAA receptor (Cromer et al., 
2002).  Additionally, the AChBP crystal structure fits well with the monomeric structure 
from the crystallized extracellular domain of the nACh receptor α1 subunit (Dellisanti et 
al., 2007). 
 A great extent of the structural information describing cys-loop LGICs was also 
contributed by Unwin and his continued work on the nicotinic receptor, achieving an 
electron microscopy image of four angstrom resolution.  Electron microscopy revealed 
some of the general topology of these receptors, such as the positioning of the five 
subunits around a central pore and secondary structures such as beta sheets (Unwin 1995, 
Miyazawa et al., 2003, Unwin 2005).   Electron microscopy of nAChRs isolated from 
membranes of the torpedo electric organ has supported the findings from the AChBP and 
has been used to guide homology modeling of the GABAA receptor transmembrane 
regions as well. 
 The crystal structure of the AChBP (PDB entry 1I9B) and electron microscopy of 
the nAChR (PDB entry 1OED) have provided reasonable templates for the design of an 
atomic model for the GABAA receptor (Cromer et al., 2002; O’Mara et al., 2005).  Figure 
1.7 presents a variety of images derived from these models.  The homology model for the 
GABAA receptor shows that residues predicted to be involved in ligand binding are 
indeed located at subunit interfaces, and indicates the presence of multiple loop structures 
surrounding the binding site (Figure 1.7C).  The presence of multiple loops has 
previously been postulated to be central to ligand binding, and their sequence locations 
are depicted in Figure 1.3. 
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 The specific residues that make contact with AChBP ligands were identified 
following crystallization of AChBP with the molecules nicotine or carbamylcholine 
bound (Celie et al., 2004) (Table 1.1).  The identical interactions are not likely to support 
GABA binding, but the aligned residues in the GABAA receptor may still be critical.  For 
instance, many of the residues that the homology model of the GABAA receptor predicts 
to surround the ligand-binding pocket are implicated, as 
described above, by mutational evidence, covalent 
labeling with reactive ligands, and SCAM.  
 We can begin to predict the role of these 
residues when they are considered in the 3-dimensional 
context provided by the homology model.  The GABA 
binding pocket is surrounded by a box of aromatic 
residues (Figure 1.7D, green residues) including β2Y157 
in loop B, β2F200 and β2Y205 in loop C, and α1F65 in 
loop D, which have the potential of binding the 
positively charged amino end of GABA via a cation-π 
bond.  Multiple positively charged arginine residues 
(β2R207 and α1R67) near the bottom of the binding 
pocket have the potential to interact with the carboxy end of GABA (Figure 1.7D light 
blue residues).  There are also a variety of side-chain interactions that may exist across 
the binding pocket and stabilize the global architecture of the pocket.  For instance, the 
proximity of β2Y157 with α1T130 may allow hydrogen bonding; and positioning of 
β2D163 and α1R120 has indicated a potential salt-bridge or hydrogen bond (Cromer et al., 
      AChBP 
 (L. stagnalis) 
     GABAA  
    (human) 
Complementary face 
W53 α1 F65* 
R104 α1 R120* 
L112 α1 L128* 
M114 α1 T130* 
Principal face 
Y89 β2 L99* 
W143 β2 Y157* 
Y185 β2 F200 
C187 − 
C188 − 
Y192 β2 Y205* 
          Table 1.1  Amino acids that have 
been found to interact with ligands 
bound to AChBP  (Celie et al., 2004) 
are listed with their aligned 
counterparts from the human 
GABAA receptor α1 and β2 subunits. 
Asterisks mark residues have 
previously been demonstrated to be 
involved in GABA binding. 
  
2002).  The research proposed here will dissect these
evidence for the nature of GABA binding.
 
Figure 1.7  Homology model of the GABA
nAChR to guide transmembrane domains and the crystal structure of the snail AChBP for the 
extra-cellular domain, O'Mara et al. (2005) have published coordinates for modeling the GABA
receptor.  A) Top down view of 
α1β2α1β2γ2.  B) Side view of the GABA
the β/α inter-subunit interface.  The six loops regions are colored pink.  D) View of 
Aromatic residues that may contribute to cation
residues that may interact with the
The threonine at position 130 is pink, and the aspartic acid at position 163 is red. 
 
 potential interactions and provide 
 
A receptor.  Using electron microscopy data for the 
the pentameric ring formed by the GABAA receptor subunits 
A receptor.  C) Side view of the extra-cellular domain of 
β
-π bonding are colored green, and arginine 
 negative carboxy terminus of GABA are colored light blue.  
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Study of ligand binding interactions using electrophysiology 
 The ability to determine how a particular mutation affects the function of the 
protein is essential to conducting a mutagenic study.  As we probe the functional and 
structural relationships of GABAA receptor mutations, we utilize a series of 
electrophysiological experiments that allow examination of the microscopic rates of 
GABA binding and unbinding.  This is not straightforward because macroscopic currents 
observed from outside-out patches are the product of complex interactions among 
microscopic processes such as ligand binding/unbinding, channel opening/closing, and 
desensitization/resensitization.  It is imperative that changes in the kinetics of 
macroscopic currents of mutant receptors be interpreted correctly.  Determining whether 
a residue is specifically involved in binding rather than another one of these processes, 
such as desensitization, requires that these processes be experimentally distinguished 
from each other.   
 When a solution containing GABA is applied to a patch, the rate of activation is 
dictated by both the rate of GABA binding and rate of receptor gating.  Chloride ions 
flowing through open receptors during GABA application produce the electrical current 
response which can be measured (Figure 1.8).  From the bound-closed state, receptors 
can desensitize, resulting in a prolonged closure even though GABA is bound.  When the 
GABA application is removed, the rate of deactivation is dictated by transitions from 
desensitization, opening and closing of channels, and GABA unbinding.   
Figure 1.8 also highlights a simplified kinetic model that represents the 
microscopic processes that GABAA receptors undergo.  Although a number of additional 
states have been proposed, it is most useful to use the simplest model with the fewest free 
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parameters that accurately represents receptor responses.  The four-state model here 
illustrates the minimal number of states that are necessary to explain observed responses.  
The macroscopic currents we measure are the summation of these processes and it is 
critical we separate them in order to determine binding rates.  Without this clarity the 
nature of changes caused by specific mutations around the GABA binding pocket cannot 
be properly interpreted. 
 To evaluate the role of individual residues in binding or gating, most traditional 
site-directed mutagenesis studies have examined how mutations affect macroscopic 
parameters such as the steady-state concentration response relationship (Amin and Weiss, 
1993; Schmieden et al., 1993; Westh-Hansen et al., 1997; Westh-Hansen et al., 1999; 
Boileau et al., 1999; Hartvig et al., 2000; Wagner and Czajkowski, 2001; Boileau et al., 
2002; Newell and Czajkowski, 2003; Newell et al., 2004; Kloda and Czajkowski, 2007; 
Padgett et al., 2007); however, the EC50 does not reflect any individual transition but is 
instead an indicator of the total time spent in all bound channel states (Colquhuon, 1998; 
Jones et al., 2001).  Thus, such studies have not provided a quantitative understanding of 
the effects of binding, gating, and unbinding when mutations are made.  Using a non-
equilibrium approach, these processes can be assessed.  Our studies use rapid-ligand 
application, capable of switching from a solution of saturating agonist concentration to a 
wash out in approximately two hundred microseconds.  The abruptness of the application 
allows the observation and distinction to be made of both desensitization and agonist 
unbinding.  Using a series of rapid-solution exchange based electrophysiological 
protocols and kinetic modeling it is also possible to directly measure microscopic agonist 
binding rates, and provide quality estimates of agonist unbinding rates.  This dissertation 
  
employed these techniques in order to thoroughly characterize the effects of spe
mutations around the GABA binding pocket
 
Figure 1.8  Example of a recording from wild
application for 500 ms.  It has three distinct phases.  First, when the patch has GABA solution 
applied, there is rapid activation
channels.  Activation is determined both by binding ([Ag] 
desensitization.  While still in GABA, receptors begin to close even though GABA is 
When the GABA solution is removed, the last phase, deactivation, occurs.  Current dissipates as 
channels close and GABA unbinds.  This is a complex process, which is determined by 
transitions in and out of desensitization (d and r) and gating (
 
. 
-type receptors using a saturating GABA 
 as chloride ions flow across the membrane through the open 
kon) and gating (β).  The next phase is 
α and β) until unbinding (
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II.  MATERIALS AND METHODS 
GABAA receptor subunit plasmids and site-directed mutagenesis 
In order to heterologously express the GABAA receptor, plasmids containing the 
sequences encoding each subunit (α1, β2, β2-GKER, and γ2S) were utilized.  Each of these 
subunits was previously cloned into pcDNA3.1 vectors (Invitrogen, Carlsbad, CA) under 
the control of a high level expression Human cytomegalovirus (CMV) promoter. 
Site-directed mutagenesis was accomplished via a PCR-based system termed 
QuikChange (Stratagene, La Jolla, CA).  For each mutant, we generated two 
complementary oligonucleotides, typically 40 to 60 bp.  They covered the codon of 
interest and incorporated a particular mismatch that altered the codon.  The QuikChange 
method relied on an ultra-high fidelity polymerase (Pfu-Ultra).  In one reaction, with both 
primers, the polymerase amplified the entire plasmid.  Following the PCR reaction, DpnI, 
which digests methylated DNA, was added in order to eliminate the original template 
from this mix.   
After DpnI digestion, 2 µl of the mixture was used for transformation into 
competent E. coli cells.  These cells were plated onto a LB-ampicillin (50 μg/ml) agar 
plate.  The ampicillin selected for cells that took up the pcDNA3.1 vector, which contains 
an ampicillin resistance gene.  After 18 hours of incubation several colonies were picked 
and used to inoculate 3 mL LB cultures with ampicillin (50 μg/ml).  Plasmid DNA from 
these cultures was then isolated using Wizard Plus SV mini-preps (Promega, Madison, 
WI).   This yielded 100 µl of pure plasmid at a concentration between 80 ng/µl to 250 
ng/µl.  The coding region of each mutant plasmid was sequenced with forward and 
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reverse primers to ensure the intended mutation was present and no additional, unwanted 
changes occurred. 
Cell culture, transfection, and labeling   
An immortal mammalian cell line, human embryonic kidney (HEK-293), was 
used for heterologous expression of GABAA receptors.  Cells were maintained in 
Minimum Essential Medium Eagle with Earle’s salts (Mediatech, Manassas, VA) 
supplemented with 10% newborn calf serum (Thermo Scientific, Waltham, MA) and 
Penicillin-Streptomycin-Glutamine (Mediatech) in a 37o C incubator under a 5% CO2 
atmosphere.   For experiments, cells were plated onto 35 mm dishes coated with poly-L-
lysine and were transfected 18 to 24 hours later using Lipofectamine 2000 (Invitrogen).   
Lipofectamine consists of cationic lipids, which interacts with the phosphate 
backbone of the nucleic acid.  This interaction is via the cationic head groups of the lipids 
and does not result in the formation of micelles or liposomes surrounding the nucleic 
acid.  The cationic lipids also mediate the interaction of the nucleic acid with the 
negatively charged cell membrane. The complex is thought to enter the cell through 
endocytosis. 
 Receptors consisting of α and β subunits, or α, β, and γ subunits were used 
throughout this study.  For αβ receptors, the following amounts of cDNA were 
transfected: 250ng eGFP, 1.5 µg of α1, 1.5 µg β2.  For  αβγ receptors the following 
amounts of cDNA were transfected: 250ng eGFP, 1 µg of α1, 1 µg β2, and 3 µg of γ2S.  
eGFP serves as a marker for cells that are transfected.  Although poorly understood, a 
high correlation exists between cells that take up and express eGFP and also take up and 
express GABAA receptors. Cells were recorded from 48-96 hours post-transfection. 
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Electrophysiology 
All recordings for this study were collected from outside-out patches excised from 
HEK-293 cells (-60 mV).  The outside-out configuration is achieved by obtaining a tight 
seal with a cell, followed by break-in using negative pressure, and then slowly drawing 
back the pipette, stretching the membrane until a portion re-seals over the tip as it 
separates from the cell.  Recordings were made using borosilicate glass pipettes filled 
with (in mM): 140 KCl, 10 EGTA, 2 MgATP, 20 phosphocreatine and 10 HEPES, pH 
7.3.  GABAA receptor agonists and antagonists were dissolved in the perfusion solution, 
which contains (in mM): 145 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, 4 mM 
Glucose, pH 7.4.  For extracellular solutions that contained >30 mM GABA, the 
concentration of NaCl was reduced to 95 mM, and a combination of sucrose and GABA 
was added to compensate for the reduced osmolarity.  The pipette solution was adjusted 
in conjunction, reducing the KCl concentration to 90mM, and adding 50mM K-gluconate 
to maintain a constant Cl- driving force.  GABA, propofol and SR-95531 were obtained 
from Sigma-Aldrich Chemicals, St Louis, Mo.  Data were collected at 10-20 kHz using 
an Axopatch 200B amplifier (Axon Instruments, Foster City, CA) and an ITC-1600 
digitizer (InstruTech, Port Washington, NY), controlled by Axograph X software 
(Axograph Scientific, Sydney, AUS).  Currents were low-pass filtered at 2-5 kHz with a 
four-pole Bessel filter, and digitized at a rate no less than twice the filter frequency. 
In vivo, GABA mediated synaptic transmission frequently occurs in less than a 
millisecond and the post-synaptic current decays in tens of milliseconds.  In order to 
study the receptor kinetics during such an event, it is necessary to apply and remove 
agonist on a similar time scale.  Rapid-solution exchange was accomplished by using a  
  
Figure 2.1  Rapid-ligand application.  
up to the flow-pipes, which are already positioned in the bath solution. 
remains stationary, the flow-pipes can be rapidly shifted from side to side in order to expose the 
electrode to the solution flowing out of any one of the four barrels.
 
four-barreled flowpipe array (Vitrodynamics, Rockaway, NJ) mounte
bimorph (Vernitron, Bedford, OH) (Figure 2.1).  The four pipes are fused in a linear 
arrangement and manually pulled down to 100 to 200 
less than 10 µm.  A computer controlled current source stimulates
position of the flowpipes with high precision, and causes enough displacement to expose 
a patch to solutions from all four pipes without moving the electrode.  The exchange time 
(the time it takes to completely clear the liquid ju
measured by examining open tip potentials during a shift.  Open tip potentials are the 
result of differences in the mobility of sodium and potassium ions, which are at different 
concentrations in the internal pipette 
to distinguish the agonist solution from the wash solution, a small amount of NaCl is 
After pulling an outside-out patch, the electrode is raised 
 While the electrode 
 
d on a piezoelectric 
µm openings separated by septa of 
 the bimorph to shift the 
nction interface between two pipes) is 
solution compared to the external solution.  In order 
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added to the agonist solution, raising the Na concentration 5 mM.  This is enough to alter 
the open tip potential.  The 10-90% exchange times are consistently under 200 µs.   
Concentration-response experiments 
To obtain concentration-response curves, current responses evoked by a series of 
GABA concentrations are compared to the current response evoked by a saturating 
concentration of GABA.  The protocol begins with the electrode and patch in wash 
solution, then the pipes shift, exposing the electrode to the solution containing a 
saturating concentration of GABA.  After 500 ms the pipes shift back and the electrode is 
in wash solution for 12 to 15 seconds in order to recover from desensitization.  Next, the 
flowpipes shift the opposite direction, exposing the electrode to a solution containing a 
sub-saturating concentration of GABA.  After 500 ms the pipes shift back and the 
electrode is in the wash solution for 12 to 15 seconds.  This protocol is repeated 5 to 15 
times and an ensemble average for the two solutions is taken.  During a stable patch the 
sub-saturating solution can be changed by switching the solution with open flow directed 
through a 4:1 (input:output) manifold preceding the flowpipe.  Although three or four 
concentrations can sometimes be tested on a single patch, only one concentration was 
tested on the majority of patches because of patch stability.  Therefore, each 
concentration-response curve relies on data from several patches. 
 For each concentration the peak current was measured in Axograph X and 
normalized to the peak current for the saturating concentration on the same patch.  For a 
given concentration the normalized values for each patch were averaged and were plotted 
against the log of the concentration of GABA using Prism 4 software (GraphPad 
Software, Inc., San Diego, CA).  Non-linear regression of the plot was performed using a 
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variable slope sigmoidal curve (Y = Ymin + (Ymax – Ymin) / (1+10^((LogEC50 -
X)*HillSlope))).   This identified the concentration that gives a half-maximal response, termed 
EC50. 
 Analysis of macroscopic kinetics: Desensitization and Deactivation phases 
During rapid-ligand application distinct desensitization and deactivation phases of 
the current response are observed.   The desensitization phase of current responses during 
a 500 ms application of a saturating concentration of GABA was used for analysis.  The 
ensemble average of such responses was taken for a given patch and was used for 
analysis.  The ensemble average was fit using Axograph X.  The time of onset of 
desensitization was set to zero, and the region of desensitization was fit with a bi-
exponential equation (Y= A1 x e-t/τ1 + A2 x e-t/τ2 + C), where t is time, Y is the total current 
amplitude at a given time, τ1 is the time constant of the fast component of decay, A1 is 
the relative amplitude of the fast component, τ2 is the time constant of the slow 
component of decay, A2 is the relative amplitude of the slow component, and C is a 
constant that accounts for the amplitude of current that remains. 
The deactivation phase following a 2-4 ms application of a saturating 
concentration of GABA was analyzed.  Ensemble averages were used.  The time of 
GABA removal was set to zero, and the region of deactivation was fit with a bi-
exponential equation (Y= A1 x e-t/τ1 + A2 x e-t/τ2). 
A weighted time constant (τw) was also calculated for each analysis.  τw = (A1/(A1 
+ A2)) x τ1 + (A2/(A1+A2)) x τ2.  This value allows for a simplified comparison of major 
changes that may occur in macroscopic rates of either phase.   
Antagonist unbinding experiments 
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During antagonist unbinding experiments, the current that is evoked by GABA 
following a pre-equilibration in SR-95531 (a competitive antagonist) is measured.  
Outside-out patches containing GABAA receptors were first exposed to a saturating 
concentration of GABA in order to establish a control response.  After returning to the 
wash solution for 12 to 15 seconds, SR-95531 was applied for 750 ms, and then rapidly 
switched to a solution containing saturating GABA.  This procedure was repeated 5 to 15 
times, and ensemble averages were used for analysis.  The entire experiment was 
repeated several times, pre-equilibrating in different concentrations of SR-95531.   
The evoked current following pre-equilibration in SR-95531 (Iant) is shaped by the 
convolution of the time course of antagonist unbinding and the waveform of the control 
current, Ictrl (evoked with no pre-equilibration in antagonist) (Figure 2.2).  
Mathematically Iant is the convolution of Ictrl and the function (a(t)) that describes the rate 
at which receptors become available due to the unbinding of SR-95531 (Jones et al., 
1998).  Therefore, a(t) can be obtained by deconvolving Ictrl from Iant.  The following 
relationship expresses this operation, where F(f(x)) is the Fourier transform of f(x): 
  A(t) = F-1(F(Iant)/F(Ictrl)) 
Integration of a(t) then gives A(t), the fraction of receptors available for binding GABA 
as a function of time.  This is the deconvolved curve and reflects the time course of 
antagonist unbinding.   This curve was fit in Axograph X with the function: 
  A(t) = [P∞ - (P∞ - P0)exp(-t/τu)]N, 
Where P0 and P∞ are the probabilities of being available initially (at t=0) and at steady 
state (as t →∞), N is the number of antagonist binding sites per receptor, and τu is the 
  
time constant of antagonist unbinding (Jones et al., 1998).  
the reciprocal of τu.    
Figure 2.2  Antagonist unbinding experiment.
are overlayed with current responses following pre
The experiment was repeated several times, pre
concentrations of SR-95531.  The fraction of receptors av
against the log of the concentration of SR
normalized Hill equation for an antagonist:
  B∞=1/(KD-SR/[SR
The best curve fits were always achieved with N=1, indicating tha
compound is bound.  This provided an accurate estimate of K
measuring koff-SR and KD-SR, the 
kon-SR = K
 Measuring the microscopic binding rate of GABA
 The microscopic binding rate
established method, the race experiment, involving competition of GABA with an 
antagonist of known kinetics.  GABA was co
koff-SR was obtained by taking 
  Current responses to a control pulse of GABA 
-equilibration in SR-95531. 
-equilibrating in different 
ailable at t=0 was plotted 
-95531 (Prism 4).  This plot was fit with the 
 
-95531]N + 1). 
t one SR-95531 
D-SR.  After directly 
kon-SR was calculated. 
D-SR / koff-SR   
 
 of GABA (kon-GABA) was measured using an 
-applied with the competitive antagonist 
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SR-95531.  SR-95531 binds in the GABA binding pocket but does not induce any 
activation.  The ratio of channels that bind antagonist to those that bind GABA depends 
on the concentrations and relative binding rates of each.  The resulting activation is 
dependent on the percent of channels that bind GABA and are hence open.  The GABA 
binding rate was determined using the ratio of the peak current generated in the presence 
and absence of antagonist.  This ratio is termed Irace, and has the following relationship to 
kon-GABA:   
kon-GABA= ([SR-95531]kon-SR)/([GABA](1/Irace – 1)). 
 
 Alternating pulses of a solution containing only GABA with a solution containing 
GABA and SR-95531 were applied in order to observe Irace.  Incubation in wash solution 
(12 to 15 seconds) separated each application.  The only uncontrolled parameters were 
Irace (measured here), and the binding rate of SR-95531 (kon-ant), which was measured 
separately.  
Mutant cycle analysis 
Mutant cycle analysis was performed on EC50 values, deactivation rates, and 
binding rates.  ∆∆G'o was calculated as RT ln (kmutant/kwild-type), where R is the ideal gas 
constant (1.987 calories/mole) and T is the absolute temperature (296 K).  Although EC50 
and deactivation rates do not provide true kinetic rate constants, comparison of 
macroscopic parameters have been previously utilized to support side-chain interactions 
and establish coupling coefficients (Kash et al., 2003; Price et al., 2007; Gleitsman et al., 
2008).  If two mutations have independent effects ∆∆G'o(1,2) = ∆∆G'o(1) + ∆∆G'o(2) .  Any 
value of the coupling energy [∆∆G'ocoupling  = (∆∆G'o(1) + ∆∆G'o(2)) - ∆∆G'o(1,2) )] that 
deviates from zero could indicate a dependence between two residues.  Due to the 
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methodological inability to determine a true standard deviation in the sample population 
for several of our measured parameters (i.e. EC50 or KD), we consider a coupling energy 
of |0.5| kcal/mol or greater sufficiently indicates two residues are dependent.  This value 
is consistent with confirmed interaction energies between two side-chains (Hidalgo and 
Mackinnon, 1995; Ranganathan et al., 1996; Horovitz, 1996).  A significant coupling 
energy may not exclusively result from a direct interaction between two residues, but 
could result from secondary interactions through a third side-chain, or could be the result 
both residues contributing to the same structural element. 
Nonstationary variance analysis 
Nonstationary variance analysis (Sigworth, 1980) was performed on responses to 
repeated 3 ms pulses of saturating GABA. As previously described (Goldschen-Ohm, et 
al., 2010; Wagner et al., 2004), mean current (I) and variance (σ2) of the repeated pulses 
were calculated at each time point.  Mean current was divided into 100 equally sized 
bins, and the variances in each bin were averaged.  The binned variance was plotted 
versus current and fit with the equation: σ2 = iI – I2/N, where i is the single channel 
current, and N is the number of channels.  Conductance was calculated by dividing i by 
the holding potential of -60 mV, which is equivalent to the driving force because the 
reversal potential for chloride is 0 mV.  The mean current (I) is dependent on N, i, and 
the open probability (Po) as follows I = N⋅Po⋅i, allowing Po-max to be calculated from 
the maximum I.  Variance resulting from slow drift, such as rundown or run-up, was 
corrected by local linear fitting of the drift, calculating the variance due to this trend at 
each point, and subtracting the drift variance (scaled by the square current amplitude) 
  
from the total variance before fi
when tested on simulated data with drift (Wagner et al., 2004).
Kinetic modeling 
Kinetic modeling was performed with home
method (Colquhoun and Hawkes, 1995a,b).  
receptor behavior (Figure 2.3
Wagner et al., 2004, Goldschen
complex variations of this model, which included a
the simplified model was equally suitable to recapitulate our data.  During optimization 
the rate constant kon and Po-max
in this study; all other parameters we
et al. (2010) and were unconstrained.  Current responses from 3 ms and 500 ms pulses of 
saturating GABA were simultaneously fit for each patch.  Following initial optimization, 
only koff, r1, d2, r2, and p were left unconstrained; and fits were repeated. Optimization 
used a simplex algorithm to minimize the amplitude
between actual and simulated currents.  
 
 
tting.  This method yields accurate estimates of i and N 
 
-written software using the Q
We utilized a simplified model of GABA
) that has previously been described (Jones et al., 1998; 
-Ohm et al., 2010).  Although we considered more 
dditional desensitized and open states, 
 were constrained to the value obtained from experiments 
re initially set to values reported by Goldschen
-weighted sum of squared errors 
 
 
 
Figure 2.3 Kinetic model.  The 7-state markov
used to simulate GABA responses (U, unbound; B, bound; 
O, open; D, desensitized). 
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Halotag® constructs and fluorescent microscopy  
The sequence for the Halotag® (Promega, Madison, WI) was inserted between 
the codons for the fourth and fifth amino acid of the mature β2 subunit and of the mature 
γ2 subunit.  These constructs were made by amplifying the Halotag® sequence (pFN22A 
vector) with two primers that contained flanking ends, one with the restriction site AscI 
and one with the restriction site FseI.  The corresponding restriction sites were inserted 
into the GABAA receptor subunit sequence using the Quikchange site-directed 
mutagenesis system.  Both the plasmid and amplified Halotag® sequence were digested 
with the two restriction enzymes and then purified.  Following a ligation reaction, 
competent E.coli cells were transformed and plated on LB-Ampicillin (50 μg/ml) plates.  
Due to a high percentage of plasmids that re-sealed and produced false-positive colonies, 
the desired construct was identified using a PCR-based colony screening method.  Each 
colony was picked, dipped into 5 ul of water inside a PCR tube, and then streaked onto a 
fresh replicate agar plate.  A standard PCR mix was added to each PCR tube containing 
primers that flanked the insert.  After thirty rounds of PCR, appropriate colonies were 
identified based on the size of the PCR product as determined by agarose gel 
electrophoresis. 
Appropriate replicate colonies were picked and used to inoculate 3 mL LB 
cultures with ampicillin (50 μg/ml).  Plasmid DNA from these cultures was then isolated 
using Wizard Plus SV mini-preps (Promega, Madison, WI).  The coding region of each 
new construct was sequenced with forward and reverse primers to ensure the intended 
mutation was present and no additional, unwanted changes occurred. 
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For fluorescent imaging experiments HEK-293 cells were plated onto poly-d-
lysine coated glass coverslips that had been placed in the bottom of 24-well plates.  The 
next day transfection with lipofectamine was carried out.  The media was changed 36 
hours post transfection and after an additional 24 hours two-step labeling experiments 
were performed. 
Sequential labeling of cells expressing Halotag® GABAA receptor subunits was 
performed first with Halotag® AlexaFluor 488 ligand (Promega) (1uM in media, 20 
min), followed by 3 rinses with warm media and a 25 minute incubation (37degree 5% 
CO2).  Then cells were labeled with Halotag® TMR ligand (Promega) (5uM in media, 15 
min), followed by 3 rinses with warm media and a 25 min incubation (37degree 5% 
CO2).  The Alexafluor 488 ligand cannot cross the cell membrane and only labels protein 
on the surface of the cells.  TMR is membrane permeable and labels intracellular protein.  
The cells were fixed immediately after labeling using 4% paraformaldehyde, 0.2% 
sucrose in 1X PBS (pH 7.5)  for 10 minutes room temperature, followed by treatment 
with 0.2% Triton X-100 in 1X PBS for 10 minutes room temperature.  The coverslips 
were placed onto glass slides with Vectashield mounting medium (Vector Laboratories, 
Inc., Burlingame, CA). 
Imaging was performed using a Nikon A1 confocal microscope (Tokyo, Japan) 
with a 40x objective.  Halotag® Alexafluor 488 (494 nm excitation, 517 nm emission) 
and Halotag® TMR (555 nm excitation, 585 nm emission) images were collected and 
analyzed using NIS-Elements Advanced Research software (Nikon).  During acquisition 
of images the gain for each PMT channel was set between 100 and 105, the laser power 
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for both 494 nm and 555 nm lasers was set to 11.5, and the pinhole was 1.1 AU.  Images 
were collected with a Galvano scanner at a 1/8 scan line speed. 
The mean intensity of the Alexafluor 488 label and the TMR label was measured 
for individual cells after subtracting background fluorescence.  Using a Bezier hollow 
tool, a region of interest was established around every cell that appeared to have 
intracellular TMR labeling, and hence expression of GABAA receptor subunits.  The 
percent surface expression was calculated as the mean intensity of Alexafluor 488 
divided by the total of Alexafluor 488 and TMR label mean intensities.  For statistical 
analysis an arcsine transform was performed on the percent surface expression.  These 
values were used with a Student's t-test, p< 0.05, in order to compare mutant and wild-
type receptors (Prism 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III.  ALANINE MUTATIONS OF GABA BINDING 
 POCKET RESIDUES DESTABILIZE THE  
LIGAND-RECEPTOR COMPLEX 
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Introduction 
          The overall objective of this study is to improve our understanding of the structure 
of the GABA binding pocket.  A variety of experiments, described in Chapter I, have 
determined that GABA binds at the β/α inter-subunit interface, yet the molecular 
interactions that mediate GABA binding remain elusive (Sigel et al., 1992; Amin and 
Weiss, 1993; Smith and Olsen, 1994; Boileau et al., 1999; Westh-Hansen et al., 1999; 
Wagner and Czajkowski, 2001; Boileau et al., 2002; Newell and Czajkowski, 2003; and 
Newell et al., 2004; Kloda and Czajkowski, 2007).  A number of studies have utilized 
site-directed mutagenesis, photoaffinity labeling, and substituted cysteine accessibility 
method (SCAM) to study the structure of the GABA binding pocket.  These studies have 
identified a multitude of residues from both the β subunit and α subunit that may form the 
GABA binding pocket.  The residues are listed in Table 3.1.  Unfortunately, the precise 
location of these residues within the binding pocket is not clear, nor is it understood how 
these residues mediate GABA binding.  Previous mutagenesis studies failed to 
distinguish the nature of the effect that arose when mutating such residues.  Relying 
mostly on comparisons of whole-cell currents and EC50 data, such studies have not 
adequately addressed whether a given residue is functionally involved in binding, 
desensitization, or gating. 
          Although the atomic structure of the GABAA receptor has not been resolved, a 
homology model provides some indication of how the GABA binding pocket might look.  
Cromer et al. (2002) made use of the crystal structure of AChBP from the snail Lymnaea 
Stagnalis to model the extracellular domain of the GABAA receptor.  The AChBP shares 
significant primary and secondary sequence with the N-terminal domain of nACh 
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receptor as well as the other cys-loop LGICs (GABAAR included).  The completed model 
illustrates the location of the numerous residues that have been implicated experimentally 
in ligand binding (Figure 1.6, Chapter I).  These residues align with loops A, B, and C of 
the β subunit, and loops D and E of the α subunit.  With a lack of high-resolution 
structural information, the homology model is our best resource for placing the identified 
residues and the predicted secondary structure of the critical loops into a three-
dimensional context.  The homology model appears to depict the precise locations of 
these structural elements; however, it is only indirect evidence and requires experimental 
support to confirm it.   
          Scanning alanine mutagenesis was performed on the residues believed to form the 
GABA binding pocket.  The objective was to establish which receptor processes, such as 
binding, unbinding, desensitization, or gating, are influenced by each residue.  In addition 
to determining EC50-GABA values for each alanine mutant, the macroscopic kinetics for 
mutated receptors were examined using rapid-ligand application techniques, which allow 
distinct desensitization and deactivation phases to be observed during GABA evoked 
currents.  The effect that a mutation has on these phases has not previously been explored 
for most binding pocket residues, and changes in desensitization and deactivation phases 
provide an initial indication as to what receptor functions are altered.  This systematic 
screen of the binding pocket established which residues similarly contribute to a given 
receptor function, specifically identifying a number of residues that appear to stabilize the 
ligand-receptor complex.  The study also identified several mutated residues with 
particularly interesting or severely altered profiles.  Such residues deserve further 
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analysis and are the subject of later chapters exploring microscopic binding rates, kinetic 
modeling, and paired mutations. 
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Results 
          The candidate residues investigated in this study are listed in Table 3.1.  Although 
this list covers many of the predicted binding pocket residues, a handful of residues are 
absent, such as α1F65, α1R67, α1R132, and β2R207, which were already being 
investigated in our lab.  In order to explore the role each residue has in receptor function, 
the wild-type side-chain was replaced with the methyl group of alanine.  Alanine 
replacement serves to remove electrostatic or hydrogen bonding interactions inherent to 
the wild type side-chains, and minimizes the potential for introducing new interactions.  
Thirteen residues were individually mutated to alanine using PCR-based site-directed 
mutagenesis.  Double stranded sequencing of the entire coding region was conducted in 
order to verify fidelity. 
 
 
Table 3.1  Expression of 
GABA binding pocket 
mutants.  Currents were 
observed during application 
of GABA on outside-out 
patches pulled from HEK-
293 cells that had been 
transfected with a mutant 
subunit along with the 
appropriate counterpart(s).  
Expression combination 
with observable current are 
marked with a √ .   (n.d.= 
data not determined, * = 
only small currents for 100 
mM GABA) 
 
 
 GABA Evoked Current 
Mutant 
Residue 
Expressing 
α1 and β2 
Expressing   
α1 and β2-
GKER 
Expressing 
α1, β2, and 
γ2 
α1L118A None √ n.d. 
α1R120A None √ n.d. 
α1I121A None None n.d. 
α1L128A None √ n.d. 
α1T130A None √ n.d. 
    
β2Y97A None None √ 
β2L99A None None None 
β2Y157A None None √ 
β2D163A None None √ 
β2F200A None √ √ 
β2T202A None None √ ∗ 
β2Y205A None None None 
β2S209A None None None 
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Expression difficulties for alanine mutants 
          Attributing a particular receptor function to a given residue using mutagenesis 
required that a discernible effect be observed after mutation.  Furthermore, no such 
assessment on receptor function can even take place if the mutant subunit fails to 
assemble.  Indeed the expression and assembly of functional receptors was impacted by 
all of the residues considered in this screen.  In every case, HEK-293 cells transfected 
with a mutant α1 subunit and wild-type β2 or wild-type α1 and mutant β2 displayed no 
GABA (30 - 100 mM) or propofol (100 - 300 uM) evoked current (Tables 3.1 and 3.2).  
Like GABA, propofol activates the GABAA receptor; however, it has a different binding 
site.  Even if GABA binding is disturbed, propofol should elicit current if receptors have 
been assembled and inserted into the membrane.  Therefore, the absence of propofol 
current suggests that all of the mutations negatively affect receptor expression or 
assembly in our system.  
In order to continue with the study two strategies were employed to rescue 
assembly.  First, a β2 variant that was developed experimentally, termed β2-GKER, was 
used.  β2-GKER has four amino acids of β2 replaced with the aligned residues found on the 
β3 subunit, D171G, N173K, T179E, and K180R (Taylor et al., 1999; Bollan et al., 2003).    
This subunit has been shown to assemble more efficiently (Bollan et al., 2003) and we 
have found no differences in kinetics, EC50-GABA, or current amplitude between β2 and β2-
GKER containing receptors (unpublished data). 
Mutant α1 subunits were expressed with β2-GKER instead of β2.  This was sufficient 
for expression of α1L118A, α1R120A, α1L128A, and α1T130A.  Mutant β2 subunits were 
reconstructed on a β2-GKER background and expressed with α1.   This was sufficient for 
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expression of β2-GKERF200A, but failed to restore functional expression of the other β2 
mutants.   
 
 
Table 3.2  Binding pocket 
mutants disrupt propofol 
activation.  Currents were 
observed during application 
of GABA on outside-out 
patches pulled from HEK-
293 cells that had been 
transfected with a mutant 
subunit along with the 
appropriate counterpart(s).  
Expression combination with 
observable current are 
marked with a √ .   (n.d.= data 
not determined) 
 
 
 
 
 
 
 
For the β2 mutants that were not rescued by β2-GKER a second strategy was 
employed, involving the expression of a different combination of GABAA receptor 
subunits.  Previously, the bulk of work in our lab studied α1β2 receptor types.  These two 
subunits are necessary to form the GABA binding site and sufficient to produce 
functional receptors.  GABAA receptors are also capable of incorporating a γ subunit by 
forming a pentamer of 2α’s, 2β’s, and a γ, instead of 2α’s and 3β’s (Connolly et al., 1996; 
Tretter et al., 1997; Farrar et al., 1999).  Co-expression of β2Y97A, β2Y157A, or 
β2D163A with α1 and γ2 led to robust GABA evoked currents.  Expression of β2T202A 
with α1and γ2 led to propofol-activated currents, but demonstrated a limited response to 
 Propofol Evoked Current 
Mutant 
Residue 
Expressing 
α1 and β2 
Expressing   
α1 and β2-
GKER 
Expressing 
α1, β2, and 
γ2 
α1L118A None √ n.d. 
α1R120A None √ n.d. 
α1I121A None None n.d. 
α1L128A None √ n.d. 
α1T130A None √ n.d. 
    
β2Y97A None None √ 
β2L99A None None None 
β2Y157A None None √ 
β2D163A None None √ 
β2F200A None √ √ 
β2T202A None None √ 
β2Y205A None None None 
β2S209A None None None 
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GABA.  These results indicate that these β2 mutations do not prevent oligomerization of 
the β/α inter-subunit interface.   
Neither GABA nor propofol currents were observed for α1I121A, β2L99A, 
β2Y205A, or β2S209A in any of these attempts.  This result suggests that these mutations 
interfere with expression, but it is also possible that receptor gating is severely disrupted.  
 
Figure 3.1  Examples of GABA concentration-response experiments for α1β2-GKER and 
mutant receptors.  Currents evoked by a saturating GABA concentration (black trace) and a 
sub-saturating GABA concentration (red trace) to the same patch are overlayed for each 
receptor type.  A 500 ms pulse of GABA was applied in all cases (black bar).  A red arrow 
indicates the peak current evoked by 100 µM GABA for L118A, L128A, and T130A.  Example 
responses are ensemble averages of 10-30 traces.  
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 Concentration-response curves shifted by alanine mutations 
A macroscopic parameter that should appear altered when mutating a residue 
involved in binding is the concentration of agonist that gives a half-maximal response, 
known as the EC50 value.  Most of the residues being explored have previously been 
demonstrated to have an effect on EC50-GABA, but such analysis was completed using a 
variety of side-chain substitutions, different expression systems, and different application 
methods.  Concentration-response experiments here allow us to verify that an alanine 
mutation in particular alters the EC50-GABA.  
They also allow us to determine what 
concentration of GABA is saturating, which 
is important for later experiments.  The peak 
current evoked by an application of a series 
of GABA concentrations was used to 
establish the EC50-GABA value of a given 
mutant (Figures 3.1 and 3.2).  Table 3.3 
includes these values for each receptor type.  
The EC50-GABA for α1β2 receptors is 7 µM, 
and the EC50-GABA for α1β2-GKER is 6 µM.  
When α1R120A is expressed with β2-GKER, a 
10-fold increase in EC50-GABA occurs.  The 
expression of β2-GKERF200A with α1 has an 
even more dramatic effect, shifting the EC50-
GABA over 130-fold.  The mutations 
Figure 3.2  Examples of GABA 
concentration-response experiments for 
α1β2γ2 and mutant receptors.  Currents 
evoked by a maximum GABA concentration 
(black trace) and a sub-saturating GABA 
concentration (red trace) to the same patch 
are overlayed for each receptor type.  A 500 
ms pulse of GABA was applied in all cases 
(black bar). Example responses are ensemble 
averages of 10-30 traces.   
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α1L118A, αL128A, and α1T130A have more subtle effects, shifting the EC50-GABA 7.5-
fold, 5 fold, and 4-fold respectively. 
The concentration-response curve for α1β2γ2 yields an EC50-GABA of 70 µM.  
β2D163A causes a modest 2.2 fold shift in EC50-GABA, while β2Y97A and β2Y157A 
dramatically shift the dose-response curves, 14-fold and greater than 400-fold 
respectively. 
The expression of α1β2T202Aγ2 yielded minimal responses to GABA (even at 100 
mM).  The fact that propofol application consistently evoked large currents in patches 
pulled from HEK cells expressing this receptor type suggests that the mutation allows 
normal receptor assembly, but significantly disrupts the GABA binding site.  Propofol 
typically activates wild type receptors with a maximum current that is only 60% of the 
maximum GABA current evoked (Davies et al., 1997; Hales et al., 2006).   For β2T202A, 
the currents evoked by propofol were 10-fold larger than the currents evoked by 100 mM 
GABA, which was the maximal concentration of GABA tested (Figure 3.3).  The greater 
propofol activation indicates functional channels are being assembled efficiently, but that 
GABA activation is severely disrupted. 
 
 
 
 
 
 
 
 
Figure 3.3  For β2T202A GABA exhibits 
limited potency relative to propofol.  For 
α1β2T202Aγ2 receptors, current responses were 
evoked by a 500 ms application of 100 mM 
GABA (black trace, black bar), followed by a 
15 second washout and a 500 ms application of 
100 µM propofol (red trace, red bar).  Example 
responses are ensemble averages of 10-30 
traces.  
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Macroscopic deactivation kinetics  
Another parameter of interest was deactivation.  Changes in deactivation can be 
the result of altered unbinding rates, closing rates, or desensitization rates.  Mutants with 
clear changes in deactivation will be of interest for further study.   The receptor kinetics 
of macroscopic deactivation were characterized following a brief (3ms) pulse of GABA, 
similar to that occurring during synaptic transmission (Figure 3.4 and 3.5).  Changes in 
the rate of deactivation often correlate to a change in the stability of the ligand-receptor 
complex.   
Initial characterization of deactivation was done by fitting bi-exponential 
functions to each trace and calculating the weighted tau (Table 3.3).    α1T130A has little 
effect on the deactivation, whereas α1L128A, β2Y97A, and β2D163A show significant 
Figure 3.4  The deactivation phase of α1β2-GKER and mutant receptors.  Currents evoked from 
a 3 ms pulse of GABA (arrow) exhibit distinct deactivation for many of the mutant receptors.  
Example responses are ensemble averages of 10-30 traces. 
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increases in the rate of deactivation.  The most dramatic deactivation effects occur with 
α1L118A, α1R120A, β2Y157A, and β2F200A, which reduce the weighted time constant 
(τw) by 9-fold, 24-fold, 12-fold, and 19-fold compared to their respective controls. 
  
Macroscopic desensitization kinetics 
The desensitization of macroscopic currents was also assessed in order to explore 
the functional affect of each mutant.  Long pulses (500 ms) of saturating GABA were 
applied to patches (Figures 3.1 and 3.2).  The resulting desensitization phase was fit with 
a bi-exponential function.  Desensitization is composed of several phases, with additional 
slower phases being revealed during prolonged exposure to GABA.  Typically, two 
phases are observed during a 500 ms pulse (generically referred to as fast and slow 
desensitization).  The rate and extent of desensitization can vary significantly for a given 
receptor type.  Although the data for the individual components is useful during detailed 
analysis, a simplified comparison of the total extent of desensitization and the τw is more 
prudent for easy comparison.  Most of these residues showed no significant 
desensitization effect when mutated to alanine (Table 3.3).  Subtle differences created by 
Figure 3.5  The deactivation phase 
of α1β2γ2 and mutant receptors.  
Currents evoked from a 3 ms pulse of 
GABA (arrow) exhibit distinct 
deactivation for many of the mutant 
receptors. Example responses are 
ensemble averages of 10-30 traces.  
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many of the mutants were overshadowed by the generally large variability in 
desensitization.   
Three mutations did significantly affect desensitization.  α1R120A has a significant 
reduction in the time constant τw.  α1L128A significantly increases the percent remaining, 
but not τw.  β2Y157A also shows a significant increase in percent remaining; however, 
desensitization experiments were carried out with a solution of 100 mM GABA, which 
may not have been saturating for this mutant.  Desensitization profiles at non-saturating 
concentrations are inherently different and could lead to a misleading result. 
A complication arose over the course of these experiments, which were conducted 
during a span greater than four years.  The rate and extent of desensitization for the 
control receptor type from 2006-2007 were distinct from data collected from 2008-2010 
(Figure 3.6).  The variables that influence desensitization are not well understood.  
Within our expression system, expression levels of endogenous proteins that modulate 
the GABAA receptor may vary.   Additional concern exists with an unintended external 
modulator that might influence receptor function.  Whether this is in our media, 
supplements, plastic-ware, or solutions is extremely difficult to deduce.  For the sake of 
Figure 3.6  α1β2-GKER exhibited 
different desensitization rates 
during 2006-2007 and 2008-2010.  
For α1β2-GKER receptors, currents 
evoked from a 500 ms pulse of 30 
mM GABA (bar) in 2006 and 2008 
exhibit unique desensitization.  
Example responses are ensemble 
averages of 10-30 traces.  
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consistency, all mutants were compared against control data collected during the same 
experimental timeframe.     
Table 3.3  Macroscopic analysis of amino acid residues lining the GABAA receptor 
ligand binding pocket.   
Construct Expression 
requirements 
EC50-
GABA 
Deactivation 
(τw) n 
Desensitization 
(τw) 
Desensitization 
(% remaining) n 
α1β2   7 µM 103 ± 14 ms 9 67 ± 15 ms 30 + 13 20 
α1β2-GKER   6 µM 96 ± 12 ms 9 
85 ± 10 ms 1;          
22 ± 3 ms 2 
28 + 12;            
19 + 11  
29 
26 
   
 
 
 
  
α1R120A β2-GKER 63 µM 4 ± 1 ms * 4 40 ± 4 ms * 31 + 12 46 
   
 
    
α1L118A β2-GKER 45 μM 11 ± 2 ms * 2 26 ± 4 ms 22 ± 3 3 
α1L128A β2-GKER 31 μM 35 ± 3 ms * 3 24 ± 7 ms 44 ± 6 * 3 
α1T130A β2-GKER 26 μM 114 ± 12 ms  2 26 ± 5 ms  33 ± 4 3 
β2F200A β2-GKER 800 µM 5 ± 12 ms * 10 23 ± 3 ms 20 + 6 26 
              
α1β2γ2   70 µM 37 ± 6 ms 14 124 ± 10 ms 39 + 2 38 
β2Y97A γ2 
1,000 
µM 12 ± 3 ms * 19 137 ± 20 ms 33 + 8 12 
β2Y157A γ2 
> 30,000 
µM 3 ± 1 ms * 3 139 ± 14 ms 61 ± 4 * 4 
β2D163A γ2 155 µM 16 ± 1 ms * 20 85 ± 6 ms 34 + 2 28 
β2T202A γ2 N.D. -  - -  
        
α1I121A No expression  - -  -    
β2L99A No expression - -  -    
β2Y205A No expression - -  - -  
β2S209A No expression - -  - -  
Desensitization for α1β2-GKER is broken into two data sets: (1) data collected from 2006-2007, and 
(2) data collected from 2008-2010.  Values are reported ± SEM and those that are significantly 
different from the appropriate control are indicated by an asterisk, determined by ANOVA with 
Dunnett’s post-test, p < 0.05.  α1R120A was the only mutant compared with the 2006-2007 α1β2-
GKER desensitization data. 
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Discussion 
The screening of residues throughout the GABA binding pocket was conducted 
with the purpose of exposing which receptor functions are influenced by a given residue, 
as well as identify a subset of residues worth exploring in more depth.    As we try to 
improve our understanding of the architecture of the ligand binding pocket, it is important 
to distinguish residues that are clearly critical for binding or gating, from those that are 
not involved.  Previous studies have utilized mutagenesis, but have not explored how 
each mutation affects the kinetics of receptors.  Our screen examined receptor kinetics 
systematically, using alanine substitution, and took a closer look at each mutation’s 
effect.  This study served as a preliminary screen to identify residues that will be further 
analyzed for their role in GABA binding.   
GABA binding pocket mutations disrupt assembly 
Mutations at the interface between two subunits commonly disrupt receptor 
assembly (Enna and Mohler, 2007).  These residues may play a major role in GABA 
binding, but a comparison cannot be made among them unless we have an observable 
GABA response.  A number of studies conducting serial mutagenesis on residues around 
the binding pocket have found particular substitutions that are not well tolerated while 
other substitutions maintain full expression/functionality (Amin and Weiss, 1993; 
Harrison and Lummis, 2006).  All of the mutations studied in this screen hindered 
functional expression of GABAA receptors and many are likely to play an important role 
in assembly.  For residues that could not be explored due to a lack of expression, 
alternative side-chain substitutions may need to be utilized.  These include L99 to valine, 
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which simply shortens the side-chain by one carbon, T202 to serine, which alters the 
orientation of the hydroxyl group, as well as S209 to threonine. 
Mutation of certain residues located on the β subunit allow the assembly of 
functional receptors when expressed with α and γ, but not when expressed with α only.  
Activation by GABA requires the proper formation of β/α inter-subunit interfaces (the 
location of the GABA binding site).  Considering what is known about the subunit 
arrangement of the GABAA receptor, the difference between these two potential receptors 
is a β/β interface versus a β/γ interface.  This suggests these residues are required in 
assembly of the β/β interface, critical for GABAA receptors composed of αβαββ subunits, 
but not αβαβγ subunits.  Chapter VII details a series of experiments designed to confirm 
the assembly effect for each mutated residue that only expresses in the presence of γ2. 
Several residues stabilize the ligand-receptor complex 
As expected, several residues of the GABA binding pocket impacted receptor 
function when mutated to alanine.  Significant shifts in EC50, and increased deactivation 
are strong evidence that a mutation destabilizes the ligand-receptor complex.  α1R120A 
and β2F200A are two mutations that exemplify destabilization of the ligand-receptor 
complex.  Both cause significant increase in EC50-GABA and their deactivation rates are 
particularly affected.  An increase in the rate of deactivation can be caused by several 
factors, but often represents an increase in the microscopic unbinding rate.  We cannot 
directly measure the rate of unbinding because deactivation depends not only on the 
unbinding rate, but also on the rates of channel opening and closing, and on the rate of 
desensitization.  However, if desensitization during a long pulse of saturating GABA is 
unchanged, a change in the relative unbinding rates between the mutant and control 
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receptor can be identified.   This is because the rate and shape of macroscopic 
desensitization depend on all of the same transitions that contribute to deactivation, 
except for agonist unbinding.  For β2F200A, desensitization is unchanged indicating an 
increased unbinding rate is causing the accelerated deactivation phase.  For α1R120A the 
weighted time constant of desensitization was reduced only 2-fold, yet the weighted time 
constant of deactivation was reduced 24-fold.  Therefore, in addition to any gating 
change associated with desensitization, an increased unbinding rate of GABA likely 
contributes to the accelerated deactivation phase for α1R120A. 
Both of these residues appear to play an important role in stabilizing the ligand-
receptor complex.  The large shifts in EC50 and deactivation suggest that they influence 
GABA affinity.  Later chapters detail the analysis of microscopic kinetics related to each 
residue, and explore structural interactions for each. 
Y97A and Y157A are two other residues that significantly shift the concentration 
response curve and speed deactivation.  Like R120A and F200A, this suggests that these 
residues have large influences over GABA affinity.  The significance of these tyrosines 
may be associated with their participation in a structural motif, termed an "aromatic box".  
Y97 and Y157, as well as F200 and Y205, are clustered closely, form a hydrophobic 
region, and are capable of forming cation-π interactions.  Homologous residues form an 
aromatic box in the nAChR, and are believed to contribute to the binding of the positive 
amine group of acetylcholine (Grutter and Changeux, 2001).  The actions of these 
GABAA receptor side-chains were hypothesized to form cation-π bonds and this question 
was addressed by Padgett et al. (2007).  They used unnatural amino acid substitution to 
introduce fluorinated aromatic side-chains, which had a decreasing potential to form 
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cation-π interactions.   This decreasing cation-π ability was compared with the effect on 
EC50.  Only Y97 showed a strong correlation and they postulated that it directly interacts 
with the amino group of GABA.  
Further investigation, particularly of the microscopic binding rate, of these 
aromatics is definitely relevant.  However, the extreme disruption caused by Y205A is 
problematic, and the EC50-GABA of Y157A may be too shifted to complete full kinetic 
analysis.  Therefore, more conservative mutants were generated: Y97F, Y157F, and 
Y205F.  These mutations maintain the aromatic ring and capability of a cation-π bond, 
but lose the hydroxyl group, a potential player in hydrogen bonding.  All of these 
expressed well with γ2. Although this subset of residues could be of great interest, it has 
not been investigated any further. 
A mutant with no significant changes in deactivation, desensitization, or EC50-
GABA is considered silent, and would not be further explored.  Of the residues tested, only 
T130A lacks a distinguishing effect.  This does not exclude all importance of the residue, 
but at minimum demonstrates that alanine is sufficient in maintaining normal function for 
this position.  The result of the threonine mutation suggests that the hydroxyl group, 
which could participate in hydrogen bonding, is not critical, or such an interaction is not 
required for the parameters we assessed.  Mutation of α1T130 to cysteine, on the other 
hand, caused a 102-fold increase in EC50-GABA (Kloda and Czajkowski, 2007); therefore 
the contribution of this side-chain is not easy to discern.   
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IV.  α1R120: A DISTINCT ARGININE  
RESIDUE IN THE GABA 
BINDING POCKET 
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Introduction 
Hypotheses about the mechanisms involved in the binding of GABA have often 
included interactions of the negative carboxy end of GABA with positively charged side-
chains, such as arginines.  As these types of interactions have been explored, a couple of 
plausible candidates have been found, specifically α1R67 and β2R207.  Interestingly, 
mutations of both of these arginines had qualitatively similar effects on receptor kinetics.  
Namely, α1R67A and β2R207A displayed significantly faster deactivation (24-fold and 
13-fold increase in the weighted time constant), but macroscopic desensitization was not 
different from wild type (Goldschen-Ohm et al., 2011).  The implication of this result is 
that each arginine plays a role in maintaining the stability of the ligand-receptor complex 
by slowing the GABA unbinding rate.  In addition, each arginine to alanine mutation 
demonstrated approximately equal and opposite shifts in unbinding and binding rates 
(Goldeschen-Ohm et al., 2011).   
The alanine mutagenesis screen presented in Chapter III identified a third arginine 
that may serve a similar capacity.  α1R120 is located near the top of the GABA binding 
pocket (Figure 4.1), and is highly conserved amongst GABAA receptor subunits.  Several 
previous studies have implicated α1R120 in GABA binding.  Westh-Hansen et al. (1999) 
showed α1R120K expressed with β2 and γ2 had a 180-fold rightward shift in the 
concentration-response curve, as well as abolished the binding of radiolabeled muscimol 
(another GABAA receptor agonist) and radiolabeled SR-95531 (a competitive 
antagonist).  Further demonstrating the strong impact of this residue, Harrison and 
Lummis (2006) made mutations of the corresponding residue in the homomeric GABAC 
  
receptor (ρ1R158) to lysine, alanine, or 
functional receptors.   
 
Figure 4.1  Homology model depicting three important arginines in the GABA binding 
pocket.  The model is derived from the AChBP (O’Mara et al., 2005).  The extracellular domains 
of a β/α inter-subunit interface are viewed from the side.  The residues are colored by CPK type.
 
With the objective of understanding the role of 
previously identified arginines, a thorough 
α1R120A was performed.  Quantifying the effect on binding kinetics allowed a more 
complete interpretation of α1R120
understanding of the similarities and differences between t
The results presented here demonstrate
glutamine.  All of these mutations resulted in non
α1R120 in the context of the 
kinetic characterization of the mutant 
’s contribution in receptor function and aided our 
he binding pocket arginines.  
 that mutation of the third binding pocket arginine, 
58 
-
 
59 
 
 
α1R120, to alanine also causes a large increase in the rate of deactivation with no effect 
on desensitization, but only causes a small decrease in the GABA binding rate.   
 
  
  
The α1R120A mutation causes significant changes in deactivation and EC
The effects of the α1R120A mutation on GABA
characterized using rapid-ligand application on 
expressing the mutant α1 subunit with a 
series of GABA concentrations was used to establish an EC
Each response was normalized to the maxi
10 mM GABA.  R120A shifted the concentration
(Figure 4.2).  A shift in the concentration
affinity, as well as by changes in the equilibr
rates of the channel (Colquhoun 1998).
Macroscopic desensitization and deactivation phases were examined during 
GABA evoked currents in order to pinpoint specific parameters 
resensitization, or GABA unbinding) 
desensitization phase represents a spontaneous and prolonged closing of channels even 
though GABA is still bound, and it is dictat
Results 
50-GABA
A receptor function were 
outside-out patches from HEK
β2-GKER subunit.  The peak current response to a 
50-GABA value for the mutant.  
mum peak current evoked, in this case using 
-response curve rightward 10
-response curve can be caused by decreasing 
ium constant of the opening and closing 
 
 
Figure 4.2  R120A shifts the GABA 
concentration-response curve right
ward.  Responses to a series of GABA 
concentrations were normalized for the 
maximum evoked current.  The da
fit with a sigmoidal curve: Y = Ymin + 
(Ymax – Ymin) / (1 + 10^((LogEC
* HillSlope)).  α1β2-GKER (
EC50 of 6 µm.  R120A (○) has an EC
63 µm. 
 
(i.e. desensitization, 
that are altered by the R120A mutation.  The 
ed by several gating processes, including the 
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-293 cells 
-fold 
-
ta was 
50 – X) 
▼) has an 
50 of 
  
rates of channel opening and closing, and the rates of desensitization and resensitization.
The deactivation phase represents the current decay following removal of GABA.  Not 
only is it influenced by the same gating processes
dictated by the GABA unbinding rate.  
Figure 4.3  R120A dramatically accelerates the rate of deactivation, but has only minimal 
effect on desensitization.  A) Curre
desensitization.  B) Currents evoked by a 3 ms pulse of GABA (arrow) exhibit distinct 
deactivation.  Example responses are ensemble averages of 10
 
During a 500ms application of GABA, th
desensitization phase appears unaffected by the 
4.1).  However, when the desensitization phase is fit with a bi
changes in the time constant 
α1R120A also displays greatly accelerated deactivation
 as desensitization, but it is also largely 
 
nts evoked by a 500 ms pulse of GABA (bar) exhibit similar 
-30 traces. 
e early “fast” component of the 
α1R120A mutation (Figure 4.
-exponential equation 
τslow, % τslow, and the weighted time constant τw 
 during a 3 ms application of 
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are evident.  
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GABA (Figure 4.3B, Table 4.1).  Although the subtle change in the desensitization phase 
suggests that channel gating is altered by the mutation, it is unlikely to account for the 
more than twenty-fold increase in the time-course of the deactivation phase.  The 
accelerated deactivation time-course could be best explained by an increased GABA 
unbinding rate.  If faster unbinding occurs, a lower apparent affinity would be expected 
because receptors would spend less time in the ligand-bound states.  The measured shift 
in EC50-GABA is consistent with this interpretation. 
Table 4.1  Summary of parameters from exponential fits of deactivation and desensitization 
Desensitization (500 ms, 10 mM GABA) 
Receptor type τ fast (ms) τslow (ms)  %τfast %τslow 
% 
Remain 
τ
w 
(ms) n 
α
1
β
2-GKER
 17 ± 5 238 ± 155 49 ± 14 23 ± 9 28 ± 12 87 ± 59 23 
R120A 15 ± 6 151 ± 113* 55 ± 17 15 ± 9* 31 ± 12 40 ± 27* 46 
 
Deactivation (2-4 ms, 10 mM GABA) 
Receptor type τ fast (ms)  τslow (ms)  %τfast %τslow τw (ms) n  
α
1
β
2-GKER
 23 ± 11 281 ± 92 71 ± 8 29 ± 8 96 ± 36 9  
R120A 3 ± 1* 34 ± 11* 94 ± 2* 6 ± 2* 4 ± 1* 4  
 
Parameters are from bi-exponential fits to the desensitization and deactivation waveforms evoked 
by 3 ms and 500 ms pulses of 10 mM GABA.  All data are reported as mean ± standard deviation.  
Significant differences between control and mutant parameters were calculated using Student’s t-
test (* p < 0.05). 
 
The a1R120A mutation causes 2-fold increases in both SR-95531 affinity and binding rate 
 The binding kinetics of the competitive antagonist SR-95531were determined 
because this molecule binds in the GABA binding pocket, and the SR-95531 binding rate 
can be used in subsequent experiments to calculate the GABA binding rate.  The 
microscopic kinetics of SR-95531 were directly measured with a series of antagonist 
unbinding experiments.  Outside-out patches were pre-equilibrated in SR-95531 before 
  
jumping into GABA.  Figure 
equilibration in SR-95531 for α
Figure 4.4  R120A does not alter the unbinding rate of SR
determined for each receptor type by examining the current response to GABA following a pre
equilibration in SR-95531.  A) Current responses to a control pulse of 10 mM GABA are 
overlayed with current responses foll
deconvolution of GABA-evoked currents with SR
pre-equilibration.  Curve fits (red lines) reveal the time course of SR
 
As the waveform of the pre
current and the antagonist unbinding time
was extracted from this data by deconvolving 
equilibrated current (Figure 4.
GKER and R120A.  The microscopic unbinding rate, which is equal to 1/
3.0 s-1 for α1β2-GKER  and 7.1 ±
 
 
 
 
 
 
 
 
 
4.4A illustrates the response to GABA following pre
1β2-GKER and R120A.   
-95531.  The koff for SR
owing pre-equilibration in 1 µM SR.  B) Plots show the 
-95531 pre-equilibration from those without 
-95531 unbinding.
-equilibrated current is the convolution of the GABA 
-course, the antagonist unbinding time
the GABA-only current from the pre
4B).  The time course of unbinding was similar for 
τu, was 7.3
 3.2 s-1 for R120A. 
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Figure 4.5  R120A shifts the SR-
95531 inhibition curve. 
Concentration-response curves for 
the equilibrium antagonist 
occupancy in the absence of 
GABA were fit to the normalized 
hill equation I/Imax = 1 – 1/[(KD-
SR/[SR-95531])N + 1].  α1β2-GKER 
(, black curve) has a KD of 47 
nM.  R120A (o, red curve) has a 
KD of 30 nM.  
 
 
 
The antagonist unbinding experiment was repeated with pre-equilibration at 
several different SR-95531 concentrations, and the microscopic affinity constant, KD-SR, 
was obtained by plotting the fraction of receptors that were unbound (and therefore 
available) at t=0 versus antagonist concentration (Figure 4.5).  The y-intercept of the 
deconvolved curve provides the fraction of receptors available (Figure 4.4B).  This plot 
was fit with a normalized Hill equation for antagonist.  R120A caused less than a 2-fold 
decrease in KD-SR.   
The microscopic binding rate was then calculated using the equation kon = koff/KD.  
For α1β2-GKER, kon-SR = 1.6 ± 0.6 x108 M-1s-1.  For R120A, kon-SR = 2.6 ± 0.9 x 108 M-1s-1, 
which was significantly different from control (Student’s t-test, p < 0.05). 
The α1R120A mutation decreases the GABA binding rate 2-fold 
The effect that the R120A mutation has on EC50-GABA and the rate of deactivation 
strongly suggests that this mutation alters GABA affinity.  Other arginine residues of the 
GABA binding pocket that alter affinity (i.e. R67 and R207) exhibit shifts in GABA 
  
binding that are proportional to their shift in unbi
R120A was measured in experiments where the competitive antagonist SR
GABA were simultaneously applied.  The current response during co
depends on the relative concentration a
parameters are known, except for the GABA binding rate
When 300 µM SR-95531 and 10 mM GABA were co
response that was 50% of the peak response to application of 10 mM GAB
(Figure 4.6).  For α1β2-GKER co
elicited a peak response that was 
percentage, termed Irace, is related to the binding rates as follows: 
kon-SR/([GABA](1/Irace -1)) (Jones et al., 1998).  The GABA binding rate was computed 
for α1β2-GKER as 2.7 ± 0.7 x 10
and they were significantly different 
Figure 4.6  R120A decreases the GABA binding rate 2
for α1β2-GKER (A) and R120A (B)
application of 10 mM GABA and 300 
10 mM GABA alone.  The two separate applications are overlayed for each receptor type. 
nding.  The GABA binding rate for 
-95531 and 
-application 
nd binding rate of each compound.  All of these 
, which can then be calculated
-applied, R120A exhibited a peak 
A
-application of 300 µM SR-95531 and 10 mM GABA
80% of the peak response to 10 mM GABA
kon-GABA = [SR95531
7
 M-1s-1 and for R120A as kon-GABA = 1.4 ± 0.7 x 10
from each other (Student's t-test, p < 0.05)
-fold.  Race experiments are depicted 
.  For both receptor types, currents evoked by simultaneous 
µM SR-95531 were compared with the current evoked by 
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Discussion 
α1R120 stabilizes the ligand-receptor complex 
α1R120 plays a significant role in receptor function, as evidenced by changes in 
EC50, deactivation, and GABA binding rate.  The large increase in the speed of 
deactivation, accompanied by a reduction in binding rate explained the shift in EC50 that 
was observed in the alanine mutagenesis screen.  The lopsided effects on apparent 
unbinding versus binding suggest α1R120 contributes more to the stabilization of the 
ligand-receptor complex than to its formation.  This is unusual in that other arginine 
residues at the GABA binding pocket (α1R67 and β2R207) all have equal effects on both 
rates (Wagner et al., 2004; Jones et al., 2005). 
Distinct roles for arginines at the GABA binding pocket 
The parameters affected by the alanine mutation of α1R120 are similar to those of 
α1R67A and β2R207A.  There were shifts in EC50, deactivation, and binding rates, but 
little change in desensitization.  However, the degrees of these effects are noticeably 
different.  α1R67A and β2R207A cause more severe shifts in every one of these 
parameters than α1R120A.  These quantitative differences indicate a distinct role or 
contribution for α1R120 that is less critical for GABA binding. 
The distinction of α1R120 from the other arginines, which may directly interact 
with GABA, is further supported by the unique actions that GABA and the antagonist 
SR-95531 mediated on methane thiol sulfonate (MTS) reactions of these three residues.  
For β2R207 and α1R67, GABA and SR-95531 interfere with the MTS reaction (Wagner 
and Czajkowski, 2001; Boileau et al., 1999).  MTS reaction with α1R120C, on the other 
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hand, is affected by SR-95531 but not GABA (Kloda and Czajkowski, 2007).  Although 
composed of similar chemical moieties as GABA, SR-95531 is a larger molecule (13.5 Å 
in length versus 4.5 Å) (Boileau et al., 2002).  This suggests α1R120 is further from the 
GABA binding site than α1R67 or β2R207. 
α1R120 indirectly contributes to the GABA binding pocket 
α1R120 is crucial for normal receptor function and its absence greatly decreases 
the potency of GABA.  However, when analyzed in the context of the other arginines 
located in the GABA binding pocket, it becomes apparent that α1R120 is less influential.  
α1R67 or β2R207 may be directly involved in coordinating GABA binding via hydrogen 
bonds between their terminal guanidinium groups and the carboxyl group of GABA.  
α1R120, however, may play an indirect role in binding.  Considering the location of this 
residue near the upper perimeter of the binding pocket, α1R120 more likely contributes to 
the global architecture of the binding pocket than interacts with GABA directly.  This 
could occur due to an impact on structural elements at the α1 face of the GABA binding 
pocket or by influencing subunit positioning in general.   
The charged nature of arginine makes it ideal for electrostatic interactions (i.e. 
salt-bridge or hydrogen bond), which could be critical for either function.  Current 
structural models indicate an aspartic acid residue (β2D163) is positioned in close 
proximity to α1R120, and the two may be capable of forming a salt-bridge or hydrogen 
bonds.  Identifying an inter-subunit interaction between α1R120 and β2D163 would 
confirm the role of these residues in the binding pocket architecture and provide distinct 
structural evidence to the location of each residue. This topic is explored in the next 
chapter. 
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V.  A STATE-DEPENDENT SALT-BRIDGE INTERACTION  
SPANS THE β/α INTER-SUBUNIT INTERFACE 
 OF THE GABAA RECEPTOR 
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Introduction 
Homology models (Cromer et al., 2002; Omara et al., 2005) derived from the 
crystallized structure of the molluscan acetylcholine binding protein (AChBP) (Brejc et 
al., 2001) have been used to generally position the residues in the binding pocket and can 
further inform us of the structural role an individual residue plays.  However, 
interpretations drawn from these models must be experimentally verified.  One 
interpretation drawn from homology models is that an arginine from the α subunit 
(α1R120) forms an inter-subunit salt-bridge with an aspartate from the β subunit 
(β2D163), and that this salt bridge is conserved at every subunit interface (Cromer et al., 
2002) (Figure 5.1).  These two residues are highly conserved among LGIC subunits and 
experimental evidence for a corresponding salt-bridge interaction has been presented for 
the γ/β inter-subunit interface of the GABAA receptor (Goldschen-Ohm et al., 2010).  
Mutagenesis studies show the GABA concentration-response curve is sensitive to 
changes at either α1R120 or β2D163 (Westh-Hansen et al., 1999; Kloda and Czajkowski, 
2007; Newell et al., 2004; see Table 3.3).  Also, SCAM studies demonstrated both 
residues are accessible to modification by sulfhydryl reactive reagents, indicating that 
they are present at the aqueous surface (Newell et al., 2004; Kloda and Czajkowski, 
2007). 
This postulated interaction between α1R120 and β2D163 was explored by 
characterizing macroscopic parameters (EC50-GABA, deactivation, and desensitization) and 
microscopic parameters (GABA binding and unbinding rates) for alanine mutations at 
each residue.  These results were then subjected to double-mutant cycle analysis to test 
for interactions.  Interestingly, mutation of both residues affected the GABA binding rate 
  
(kon-GABA), independently.  However, when analyzing the deactivation time constants or 
the GABA unbinding rates, the two residues appear to be coupled.  These results suggest 
that α1R120 and β2D163 form a state
 
Figure 5.1  Homology models of the GABA
β2D163 and α1R120.  A) View from the extracellular side looking through the channel pore.  
β2D163 (red) and α1R120 (blue) are located at the 
mutated at both interfaces.  B)  Side view of the extracellular domain at a single 
The nearest charged atoms of 
representative human GABAA
acetylcholine receptor subunits aligned with the acetylcholine binding protein sequence, 
demonstrates the conservation of the residues mutated in this study
-dependent salt-bridge. 
A receptor depict a putative salt-bridge between 
β/α inter-subunit interfaces.  Residues were 
β
α1R120 and β2D163 are 3.6 Å apart.  C)  Sequences of 
 receptor, glycine receptor, 5-HT3A receptor, and n
 (in bold). 
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Results 
In homology models β2D163 and α1R120 are juxtaposed across the “top” of the 
GABA binding pocket.  In order to further explore the roles of these residues in receptor 
function, and to determine if they functionally interact, each wild type side-chain was 
replaced with the methyl group of alanine.  Alanine replacement serves to remove 
electrostatic or hydrogen bonding interactions inherent to the wild type side-chains, and 
minimizes potentially confounding interactions from the introduced side-chain.  
Receptors containing the α1R120A mutation, the β2D163A mutation, or both mutations 
were characterized. 
β2-GKER rescues α1R120A expression and γ2 rescues β2D163A expression 
HEK 293 cells transfected with wild-type β2 and α1R120A display no GABA (100 
mM) or propofol (300 uM) evoked current. The propofol binding site is distinct from the 
GABA binding site where α1R120 is located. Therefore, it is likely that the α1R120A 
mutation negatively affects receptor assembly in HEK-293 cells.  In order to rescue 
assembly, the β2-GKER construct was utilized.   β2-GKER contains four point-mutations 
where a given residue is replaced with its counterpart from the β3 subunit.  This construct 
has been shown to rescue expression of another binding site mutant, α1R67A,  (Bollan et 
al., 2003) and has subsequently been used in our lab to restore assembly of several other 
mutant constructs (unpublished data).   
Transfections with wild type α1 and β2D163A also failed to display GABA or 
propofol evoked currents.  In an attempt to rescue expression, the β2D163A mutation was 
recreated in the β2-GKER background, but this construct failed to give current.  Ultimately, 
co-transfection with the γ2 subunit was necessary to obtain robust GABA-evoked 
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currents.  To ensure adequate expression and to control for any influence of the γ2 
subunit, this study was performed using cells transfected with α1β2-GKERγ2, α1β2-
GKERD163Aγ2, α1R120Aβ2-GKERγ2, or α1R120Aβ2-GKERD163Aγ2, which shall be referred 
to from here on as wild-type, D163A, R120A, or R120A/D163A respectively. 
The sensitivity of this region to mutations was additionally observed during our 
attempts to express charge reversal mutants of each residue (D163R and R120D), alone 
or in concert as a charge swap.  Transfection with either charge reversal or the swap 
failed to express functional receptors.   
Double-mutant cycle analysis of D163A and R120A using EC50-GABA yields a weak 
coupling energy 
 
The primary goal of this study was to determine whether β2D163 and α1R120 
participate in an inter-subunit salt-bridge.  A tool that can be used to this end is the 
method of double-mutant cycle analysis, which quantifies the coupling energy between 
two mutated residues and clarifies the likelihood of two residues interacting (Horovitz, 
1996).  One parameter that has been commonly used for double-mutant cycle analysis in 
the study of LGICs is the apparent affinity for ligand, or EC50 (Kash et al., 2003; Price et 
al., 2007; Gleitsman et al., 2008).  Therefore, the effects of the D163A and R120A 
mutations were initially characterized by determining the peak current EC50-GABA value 
through concentration-response experiments.  The D163A mutation caused a 2.4-fold 
increase in EC50-GABA  (155 µM) compared to the wild-type (65 µM), whereas the R120A 
mutation had a much larger effect on EC50-GABA causing a 14-fold shift to 900 µM.  
Receptors containing both mutations displayed a 25-fold increase in EC50-GABA (1600 
µM) (Figure 5.2A).    
  
Figure 5.2  Mutant cycle analysis of EC
coupled.  A) GABA concentration
α1R120 and β2D163 when measuring peak GABA responses.  B) The mutant cycle for these 
alanine mutations.  Equations for calculating the change in free energy associated with 
mutation and the overall coupling energy are listed in the methods.
EC50 values were input into a mutant cycle to obtain a coupl
kcal/mol (Figure 5.2B, Table 
with respect to EC50-GABA, we would expect the coupling energy to be 0 kcal/mol.  Any 
value that significantly deviates from zero may 
typically a more stringent criterion (
utilized to identify direct interactions between two side
Although studies of LGICs commonly use EC
energies, these results can be confounded by the complex nature of the EC
depends on multiple microscopic processes that underlie both ligand affinity and channel 
gating (Colquhoun, 1998; Gleitsman et al., 2008).  Therefore, coupling energies 
calculated from EC50 values may be skewed, particularly when exploring in
influence multiple parameters or exist only in certain receptor states.  The significance of 
50-GABA indicates α1R120 and β2D163 are weakly 
-response curves for single and double alanine mutations at 
 
ing energy of 0.2 
5.2).  If β2D163 and α1R120 are functionally independent 
theoretically indicate coupling, but 
i.e. a coupling energy of at least |0.5| kcal/mol) is 
-chains (Horovitz, 1996)
50 values to derive thermodynamic 
50 
teractions that 
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the weak coupling energy found here is unclear, and an interaction between β2D163 and 
α1R120 cannot be confirmed or excluded with this evidence.  
D163A and R120A independently reduce the GABA binding rate  
Since analysis of EC50-GABA was indeterminate, the microscopic binding rates for 
GABA for each construct were directly measured using race experiments, as previously 
described by Jones et al. (2001).  Briefly, the first step in this process is to directly 
measure the binding rate for a competitive antagonist, in this case SR-95531.  Once the 
binding rate for SR-95531 (kon-SR) is determined, the binding rate of the agonist, GABA, 
can be measured by performing an experiment in which GABA and SR-95531 are co-
applied.  The resulting current is compared to the current evoked by an application of 
GABA alone.  The extent to which the peak current is reduced by the presence of 
antagonist depends on the relative binding rates of the two compounds.  Since the binding 
rate of SR-95531 has been determined, the binding rate of GABA (kon-GABA) can be 
calculated. 
The binding kinetics of the competitive antagonist SR-95531 were characterized 
for each receptor type.  Antagonist unbinding experiments were employed as previously 
described (Jones et al., 2001), and the dissociation constant (KD-SR) and microscopic 
unbinding rate (koff-SR) for each receptor type was measured (Figure 5.3).   Each mutant 
construct causes a small, albeit significant, (≈ 30%) reduction in koff-SR, but there are no 
significant changes in KD-SR (Table 5.1).  kon-SR, which was determined using the equation 
kon-SR = koff-SR/KD-SR, was also not significantly affected by any of the mutations. 
 
 
  
Table 5.1  Summary of microscopic binding and unbinding rates and macroscopic affinity 
for the competitive antagonist SR
 
Wild-type 
D163A 
R120A 
R120A/D163A 
Figure 5.3  Microscopic kinetics for the 
antagonist SR-95531.  A) The K
for SR-95531 was determined for each 
receptor type by examining the current 
response to 30 mM GABA following a pre
incubation in a series of concentrations of SR
95531 (1 µM shown).  B) Deconvolution of 
GABA-evoked currents after SR
equilibration from control currents (no pre
equilibration) reveals the time course of SR
95531 unbinding.  Deconvolutions were fit to 
the equation A(t) = [P∞ - (P∞ - 
where A(t) is the fraction of available 
receptors (antagonist not bound at any site), 
and P∞ are the probabilities that a single 
binding site is available initially at t=0 and at 
steady state as t→∞, τu is the time constant of 
antagonist unbinding from each site (
1/τu), and N is the number of binding sites 
(Jones et al., 2001).  C) Dose response curves 
for the equilibrium antagonist occupancy in the 
absence of GABA A(t=0) were fit to the 
normalized hill equation I/Imax 
SR/[SR-95531])N + 1]. 
 
 
 
 
 
 
 
 
 
-95531 
KD-SR koff-SR 
140 nM 15.9 ± 0.8 s-1 1.2 ± 0.1 x 10
110 nM 10.3 ± 0.7 s-1
 * 9.7 ± 0.6 x 10
100 nM 11.5 ± 0.4 s-1
 * 1.2 ± 0.1 x 10
100 nM 11.1 ± 0.9 s-1 * 1.2 ± 0.1 x 10
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Figure 5.4A depicts the results of the race experiment.  The ratio of the peak 
response of co-application to the peak response to a control application of 
the result of the relative binding rates and concentrations of GABA and SR
Using this ratio, termed Irace, the GABA binding rate can be computed as 
[SR95531] kon-SR/([GABA](1/I
and 300 µM SR-95531 gave an I
for the same concentrations I
slower binding rate for GABA.  R120A and R120A/D163A receptors require
increase in the concentration of GABA (30 mM) co
obtain Irace values of 0.37 ± 0.03 and 0.31 ± 0.01 respectively, indicating even greater 
reductions in the GABA binding rate than seen for D163A receptors.  Indeed
Irace values are used to calculate 
GABA binding rates (wild-type: 7.4 ± 0.4 x 10
R120A: 8.3 ± 0.8 x 105 M-1s-1
 
GABA alone is 
-95531.  
kon-
race -1)) (Jones et al., 1998).  Application of 3 mM GABA 
race ratio of  0.41 ± 0.04 for the wild-type receptor, while 
race was reduced to 0.27 ± 0.01 for D163A, indicating a 
-applied with 300 µM SR
kon-GABA, all of the mutants display significantly reduced 
6
 M-1s-1; D163A: 4.3 ± 0.5 x 10
; R120A/D163A: 5.0 ± 0.3 x 105 M-1s-1).   
 
Figure 5.4  GABA binds more slowly to R120A, 
D163A, and R120A/D163A.  Race experiments of 
either single alanine mutation or the double alanine 
mutation of α1R120 and β2D163.  For wild
D163A receptors, currents evoked by simultaneous 
application of 3 mM GABA and 300 µ
(gray traces) were compared with the current evoked 
by 3 mM GABA alone (black traces).  For R120A and 
R120A/D163A receptors, currents evoked by 
simultaneous application of 30 mM GABA and 300 
µM SR-95531 (gray traces) were compared with the 
current evoked by 30 mM GABA alone (black traces).  
The two separate applications are overlai
receptor type, and the peak current evoked by co
application is indicated with an arrow.   
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When these numbers are subjected to double-mutant cycle analysis the resulting 
coupling energy is effectively nil (-0.03 kcal/mol) (Table 5.2).  Therefore, the mutations 
R120A and D163A demonstrate additive effects on the GABA binding rate, strongly 
indicative of an independent relationship.  During the binding process, a salt-bridge 
between these residues is either irrelevant or non-existent.  
D163A and R120A accelerate the deactivation phase and display significant coupling 
Each mutation causes significant changes in EC50 and the GABA binding rate; 
therefore, it is evident that these residues are important for normal receptor function.  
Examination of the macroscopic kinetics associated with GABA-evoked currents allowed 
us to further uncover the impact each mutation has on receptor function. The kinetics of 
macroscopic deactivation were characterized following a brief (3 ms) pulse of saturating 
GABA, similar to that occurring during synaptic transmission (Figure 5.5).  When the 
deactivation time constants were extracted by fitting bi-exponential functions it was 
observed that both single mutations significantly accelerated deactivation (wild-type: τw= 
37.4 ± 5.5 ms; D163A: τw =15.6 ± 1.2 ms; R120A: τw = 3.5 ± 0.2 ms).  Also, the double 
mutant has the same deactivation time constant as R120A (R120A/D163A: τw = 3.5 ± 0.3 
ms). 
Double-mutant cycle analysis of the deactivation time constant revealed a 
significant coupling energy of 0.5 kcal/mol (Table 5.2).  This coupling energy suggests 
that the contributions of β2D163 and α1R120 to the function of deactivation are not 
independent, but rather that they interact during this phase. Deactivation has a very 
complex nature and is comprised of numerous microscopic parameters, any of which 
could be functionally coupled for β2D163 and α1R120.  Changes in the deactivation phase 
  
are often associated with changes in the microscopic unbinding rate, but other transitions 
such as desensitization and channel closing can influence deactivation (Jones and 
Westbrook, 1995).  In order to investigate which of these microscopic transitions are 
responsible for the coupling found in the deactivation time constants of 
α1R120, I performed kinetic modeling as presented in a later section.   
Figure 5.5  Deactivation is faster for R120A, D163A, and R120A/D163A.
current responses to a 3 ms pulse
response is overlaid with the normalized wild
weighted time constants (τw) for deactivation, generated from bi
macroscopic currents.  τw is computed as 
constant of component i. 
 
 
R120A suppresses desensitization
Further assessment of macroscopic data was conducted to explore the functional 
effect of D163A and R120A, as well as to 
modeling.  Macroscopic desensitization was characterized during a long (500ms) pulse of 
saturating GABA and the resulting desensitization phase was fit with a bi
function from which a weighted ti
D163A, which had little effect on desensitization, R120A and R120A/D163A show a 
visible reduction of desensitization in raw traces (Figure
weighted τ values revealed R120A and R120A/D1
β2D163 and 
 
  A) Macroscopic 
 of saturating GABA (indicated by arrow).  Each mutant 
-type response (light gray).  B) Summary of 
-exponential fits of the 
Σai ⋅ τi/Σai where ai and τi are the amplitude and time 
 
provide additional constraint for kinetic 
-exponential 
me constant was calculated (Figure 5.6).  Unlike 
 5.6A).  Comparison of the 
63A have significantly slower 
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desensitization (wild-type: τw
23 ms; R120A/D163A: τw= 242 ± 33 ms) (Figure 5.
displayed by R120A and R120A/D163A is similarly reduced, un
which remains normal (wild-
R120A/D163A: 39 ± 3%) (Figure 5.
Figure 5.6  Macroscopic desensitization during a long GABA pulse.
responses to a 500 ms pulse of
mutant response is overlaid with the normalized wild
Macroscopic currents for all receptor types were fit with a bi
several responses for R120A and R120A/D163A only required a mono
B) Summary of weighted time constants for desensitization.  C) Summary of the extent of 
desensitization after 500 ms. 
Microscopic unbinding rates are strongly coupled for 
In order to determine the microscopic basis for the coupling of deactivation 
effects caused by D163A and R120A
employed (Figure 5.8A) (Jones and Westbrook, 1995; Wagner et al., 2004; Barbe
= 124 ± 10 ms; D163A: τw= 85 ± 6 ms; R120A: τ
6B).  The extent of desensitization 
like that of D163A, 
type: 61 ± 2 %; D163A: 66 ± 2%; R120A: 53 ±
6C).   
  A) Macroscopic current 
 saturating GABA (indicated by a black bar above trace).  Each 
-type response (light gray).  
-exponential equation, although 
-exponential during fits.  
D163A and R120A 
, a previously established 7-state kinetic 
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w= 218 ± 
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(B and C) 
model was 
ris et 
  
al., 2007; Goldschen-Ohm et al., 2010).  This is a simplified model that recapitulates the 
dominant features present in our macroscopic 
known features of GABAA receptor physiology including two binding ste
and Clapham, 1985), multiple open states (Macdonald et al., 1989), and desensitized 
states that can occur prior to ope
step was utilized, as was required by Goldschen
to consistently simulate our experimental data.
Figure 5.7 Nonstationary variance analysis demonstrates that these mutations do not affect 
the peak open probability (P
each receptor type.  Data points were fit with a parabola (black line) describing the single channel 
conductance, Po-max, and the number of channels present in each patch, none of which differed 
between constructs (Student's t-
 
Prior to model optimization
(Figure 5.7) (Sigworth, 1980).  This assessment provides a measure of both the single
αβγ receptor data.  It incorporates several 
ps (Bormann 
ning (Burkat et al., 2001).  Also, an unlinked unbinding 
-Ohm et al. (2010), which was necessary 
 
o-max).  Plots are of normalized mean current versus variance for 
test). 
, nonstationary variance analysis was performed 
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channel conductance and maximal open probability (Po-max) of each receptor type, which 
can be used to further constrain our modeling.  None of the mutations altered 
conductance (γ) at -60 mV or the Po-max (wild-type: γ = 32 ± 3 pS, Po-max = 0.59 ± 0.05; 
D163A: γ = 33 ± 3 pS, Po-max = 0.55 ± 0.03; R120A: γ = 29 ± 3 pS, Po-max = 0.58 ± 0.06; 
R120A/D163A: γ = 31 ± 3 pS, Po-max = 0.57 ± 0.04).   
Current responses were simultaneously fit to 3 ms and 500 ms pulses of saturating 
GABA for each receptor type.  Initially, kon and Po-max were fixed to their experimentally 
determined rates and the remaining parameters were set at the values previously reported 
by Goldschen-Ohm et al. (2010).  The model was then optimized under relatively tight 
constraints until values for the opening and closing rates (α1, β1, α2, β2), as well as for 
entry into D1, were obtained that gave consistently good fits to our data.  These values 
were identical for all constructs except for the opening rate of the dominant open state 
(β2), which varied for each mutant to account for the slower rise times observed for the 
mutant constructs during responses to saturating concentrations of GABA (Figure 5.9).  
With these values constrained, a second optimization run was performed in which only 
the unbinding rates (koff) and the rates for entering and leaving the doubly-bound 
desensitized state (D2) were allowed to vary.   
Our model quantitatively reproduced both wild-type and mutant data (Figure 5.8B 
and C).  The models for all three of our mutant constructs display slower binding and 
faster unbinding of GABA relative to wild type.  The models for R120A and 
R120A/D163A also have slower entry and a more rapid exit from the doubly-bound 
desensitized state (D2).  When double-mutant cycle analysis is applied to the modeled 
unbinding rates, coupling energies of 0.63 kcal/mol and 0.34 kcal/mol were calculated for 
  
koff1 and koff2, respectively (Table 
are the basis for the coupling seen in deactivation.  
Figure 5.8  Kinetic modeling demonstrates that the effects of R120A, D163A, and 
R120A/D163A can be similarly explained by faster unbinding rates, while differential 
changes in desensitization occur.
responses (U, unbound; B, bound; O, open; D, desensitized).  B) Rate constants used to 
simultaneously simulate responses to short and long pulses of saturating GABA for wild
D163A, R120A, and R120A/D163A.  The units are s
M-1s-1.  Only koff1, r1, d2, r2, and p are reported as ± standard error because they were allowed to 
vary while the model was optimized.  C) Current responses (black trace) and simulated responses 
(red trace) to both short and long pulses of GABA are displayed for e
 
5.2). This indicates that coupled effects on unbinding 
 
  A) The 7-state markov model used to simulate GABA 
-1
 except for GABA binding steps, which are 
ach receptor type.
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Figure 5.9  The rise times during activation of GABA responses were measured from 10
90% (baseline to peak).  The activation rates (1/rise
concentration for each receptor type.  A quality fit to the equation (Y = (Rmax * [GABA]) / (K
+ [GABA]), where Rmax is the maximum activation rate) could only be achieved for wild
and D163A. 
 
 
Table 5.2  Summary of macroscopic and microscopic parameters used for double
mutant cycle analysis 
 
Wild-type 
EC50-GABA 65 µM 
Deactivation 
τw 
37.4 ms 
kon 
7.4 x 106  
M-1s-1 
koff1 8 s-1 * 
koff2 271 s-1 * 
 
 
 
 time) are plotted against GABA 
D163A R120A R120A/D163A |∆∆
155 µM 920 µM 1600 µM 0.2 kcal/mol
15.6 ms * 3.5 ms * 3.5 ms * 0.5 kcal/mol
4.3 x 106  
M-1s-1 * 
8.3 x 105  
M-1s-1 * 
5.0 x 105  
M-1s-1 * 
0.03 kcal/mol
21 s-1 * 118 s-1 * 108 s-1 * 0.63 kcal/mol
485 s-1 * 1072 s-1 * 1079 s-1 * 0.34 kcal/mol
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Discussion 
In order to build upon our understanding of the structure of the GABA binding 
site and the functional significance of specific residues, I experimentally tested for the 
existence of an interaction across the β/α interface between β2D163 and α1R120.   It has 
been demonstrated that mutating either residue alters the GABA concentration-response 
curve, but whether either of these residues is involved in binding, gating, or 
desensitization has been speculative.  Here the residues were mutated to alanine and 
double-mutant cycle analysis was applied to a variety of macroscopic and microscopic 
parameters.  Intriguingly, the residues appear to be completely independent when 
considering the binding of GABA, but they are coupled when looking at the unbinding of 
GABA.  These results suggest that β2D163 and α1R120 do not interact in the unbound 
state but form an interaction upon binding of GABA.  
Evidence for a salt-bridge between β2D163 and α1R120 
The effects on unbinding (koff1) for β2D163A and α1R120A were coupled with an 
energy of 0.63 kcal/mol.  This energy is slightly lower than, but consistent with energies 
reported for confirmed surface salt-bridges in other proteins (0.86 kcal/mol and 0.95 
kcal/mol) (Horovitz et al., 1990; Makhatadze et al., 2003).  Low coupling energies are 
expected because salt-bridges at solvent-exposed surfaces of a protein have significantly 
weaker interactions compared to those buried in the hydrophobic interior.  In the case of 
β2D163 and α1R120, both are exposed to the aqueous environment, as demonstrated by 
SCAM studies (Kloda and Czajkowski, 2007; Newell et al., 2004).  Additionally, the 
strength of a salt-bridge is influenced by the distance between the two residues.  In 
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homology models of the GABAA receptor, the nearest charged groups of β2D163 and 
α1R120 are 3.6 angstroms apart (O’Mara et al., 2005), just within range for a salt-bridge.  
Because the coupling energy between pairs of residues decreases with distance, the 
weaker coupling energy measured in our experiments may be the consequence of this 
distance.  Therefore, the coupling energy observed with β2D163A and α1R120A likely 
represents the loss of a salt-bridge. 
 It is also important to acknowledge additional interpretations to a significant 
coupling energy.  A predicted interaction may not exclusively be direct, but could result 
from secondary interactions through a third side-chain, or could be the result of indirect 
coupling due to broader structural rearrangements or conformational changes.  Although 
such possibilities cannot be ruled out, the presumed proximity of these residues suggests 
a direct interaction. 
A state-dependent interaction 
Double-mutant cycle analysis indicates that an interaction between β2D163 and 
α1R120 occurs during GABA unbinding, but not binding steps.  A state-dependent 
interaction is not difficult to envision, where these residues are coupled during the GABA 
bound state, but not during the unbound state.  In the unbound receptor no interaction is 
present; when GABA binds, conformational changes occur that move the residues into 
position to interact.  Conformational rearrangements in response to GABA binding are 
expected and repeatedly observed in studies of the binding pocket (Wagner and 
Czajkowski, 2001; Newell et al., 2004; Muroi et al., 2006).  β2D163 and other residues on 
loop B of the β2 subunit have been shown to undergo rearrangements in response to 
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receptor activation (Newell et al., 2004).  This movement may underlie the state-
dependence of the interaction between β2D163 and α1R120.   
State-dependent electrostatic interactions have previously been proposed in Cys-
loop receptors for residues coupled to the open state of the nAchR (Kash et al., 2003; 
Gleitsman et al., 2008).  Additionally, there is growing evidence in the field of protein 
structure supporting the occurrence of salt-bridge switching, especially where networks 
of charged residues are involved (Law and Lightstone, 2009).  Transient salt-bridges may 
underlie a mechanism governing conformational changes and stabilization of specific 
receptor states.  Regarding the residues studied here, both aspartic acid and arginine are 
capable of forming dual interactions.  Aspartic acid has two partial negative charges 
distributed between the two oxygen atoms of the carboxylic group; and arginine has three 
protonated nitrogens in its guanidinium group.  No additional interactions for β2D163 and 
α1R120 have been identified; however, a number of polar side-chains are found in close 
proximity and either residue could also form hydrogen bonds with backbone amides and 
carbonyls.  The ability of each residue to form multiple electrostatic interactions or easily 
switch partners may be crucial for normal receptor function.  For example, mutation of 
α1R120 to lysine, which only has a single amino group and exists in less flexible 
geometries than arginine, causes dramatic shifts in EC50-GABA (Westh-Hansen et al., 
1999). 
Discontinuity in functional effects 
β2D163 and α1R120 appear to interact in the ligand-bound state; however, the  
residues have  asymmetric roles in desensitization.  α1R120A displays greatly reduced 
desensitization, while β2D163A displays desensitization indistinguishable from wild type.  
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These residues, as part of a dynamic region, may stabilize the bound-closed receptor 
without necessarily influencing the rate-limiting transitions of desensitization. The 
additional effect observed for α1R120A may be the byproduct of its involvement in a 
complex electrostatic network.  It is highly probable that a simple binary interaction is 
not occurring between β2D163 and α1R120.  Several examples of an arginine residue 
simultaneously making multiple interactions have been identified (Horovitz et al., 1990; 
Borders et al., 1994).  The multifaceted functional group of α1R120 may be participating 
in an additional interaction that is separate from β2D163 and is critical to desensitization 
transitions.  Under these circumstances, an interaction between β2D163 and α1R120 could 
exist in all bound receptor states, and still yield asymmetric effects when either is 
mutated. 
Functional role of β2D163-α1R120 interaction 
The interaction between β2D163 and α1R120 appears to be highly conserved, not 
just at the β/α interface where a negative and a positive residue are found at these 
positions on every isoform of β and α subunits, but also at other inter-subunit interfaces.  
Recently, a corresponding interaction at the γ/β interface was identified (Goldschen-Ohm 
et al., 2010).  This interaction consisted of a triad of charge residues (β2R117, γ2E178, 
and γ2R43) forming a salt-bridge network.  The additional arginine (γ2R43) is conserved 
at the β/α interface (β2R28), but was not investigated in our current study.  This 
conserved motif may play an important role in establishing the architecture at each 
subunit interface.   
Goldschen-Ohm et al. (2010) reported that mutation at any of the residues in this 
motif slowed deactivation following a GABA response.  Not only is this significant 
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because it demonstrates that a homologous interaction influences ligand binding at other 
subunit interfaces, but it is also significant because disruption of this interaction at the γ/β 
interface had the opposite effect of disruption of the corresponding interaction at the β/α 
interface.  Mutation of either β2D163 or α1R120 significantly increases the rate of 
deactivation.  This inter-subunit motif is likely involved in subunit positioning.   In this 
scenario, breaking of the interaction at the β/α interface may increase the distance 
between the β and α subunits, speeding unbinding, whereas breaking the interaction at 
the γ/β interface may reduce the distance between the β and α subunits at the β/α 
interface, slowing unbinding.   
The GABA binding site is involved in desensitization 
This study is the first to offer in depth characterization of an α1R120 mutation.  It 
provides results that demonstrate α1R120 has important roles in GABA 
binding/unbinding and desensitization.  It should not be lost in this discussion that 
α1R120 is the first residue at the GABA binding pocket that shows a dramatic influence 
in desensitization (particularly the early, fast phase).  Most work regarding 
desensitization has focused on the transmembrane domains, and previous studies have 
demonstrated a significant role for the pre-M1 region in transducing desensitization to the 
pore surrounded by the TM2 domain (Bianchi and Macdonald, 2002).  The identification 
of α1R120 may provide a unique focus for studying how desensitization is transduced 
from the GABA binding site. 
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VI.  β2F200: A NOVEL RESIDUE INVOLVED 
IN GABA BINDING 
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Introduction 
The phenylalanine residue at position 200 on the β2 subunit is located amongst a 
number of residues believed to contribute to the ligand binding pocket, and the 
participation of aromatics, such as phenylalanine, in the ligand binding site is a conserved 
theme for cys-loop receptors.  However, there has been little evidence to date that β2F200 
plays a significant role in binding.  The crystallized structure of AChBP revealed a box of 
aromatics surrounding the quaternary ammonium of a HEPES molecule (Brejc et al., 
2001).  This motif has also been shown in 
nAChR where many of the corresponding 
aromatics have been implicated in 
binding via site-directed mutagenesis and 
photo-affinity labeling experiments 
(Grutter and Changeux, 2001).   β2F200 
aligns with Y190 of the nAChR α 
subunit, which is covalently labeled by 
both radioactive agonists and antagonists 
(Dennis et al., 1988; Abramson et al., 
1989; Grutter et al., 2000).  This indirect evidence suggests β2F200 belongs to a similar 
cluster of aromatic residues at the GABA binding site.   
β2F200 is located on Loop C, which contributes to the GABA binding pocket 
(Figure 6.1).  Loop C does not have a regular secondary structure and appears to be an 
extended coil or loop (Wagner and Czajkowski, 2001).  This loop is believed to extend 
over the site of GABA binding, perhaps occluding it.  It is a dynamic region and 
Figure 6.1  Homology model of the GABAA 
receptor.  A side view of the extracellular 
domain at a single β/α inter-subunit interface.  
β2F200 is depicted in green. 
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movements have been shown to occur during GABA activation, which may cause the 
loop to constrict over the bound GABA molecule (Wagner and Czajkowski, 2001).   
Cysteine mutation of many Loop C residues, including F200, causes a significant 
reduction of GABA affinity (Wagner and Czajkowski, 2001).  Although this implicates 
F200 in GABA binding, SCAM experiments found that reaction with MTS reagents did 
not alter GABA responses for the N-terminal residues of Loop C (V199-T202).  The 
SCAM result suggested that F200 may not face the binding pocket and has cast doubt 
over its role in GABA binding. 
Despite the evidence that GABA currents were not affected by MTSEA-biotin 
modification of F200C, F200 was investigated here as a potential binding pocket residue.  
After mutating F200 to alanine, electrophysiological experiments were performed in 
order to assess several macroscopic and microscopic parameters of receptor function.  
F200A not only shifted the concentration-response curve to the right and accelerated 
deactivation, but also caused a reduction in binding rates of GABA and SR-95531.  This 
data supports a previously unsuspected role in GABA binding for F200.     
 
 
 
 
 
 
 
  
GABAA receptor function is sensitive to mutation at position 200 of the 
Characterization of the alanine mutation at position 200 on 
on a β2-GKER background.  Subsequent concentration
GKERF200A caused a 130-fold rightw
EC50 is often assumed to be the result of a reduction in GABA affinity, although a 
reduction in channel gating could also contribute.  
 
 
 
 
Mutational effects on 
macroscopic desensitization phase during a long pulse
desensitization waveform is the result of the interaction of numerous microscopic 
processes, including channel desensitization and resensitization, and channel opening and 
closing.  If any of these gating processes are altered, m
reflect this.  During a 500ms pulse of saturating GABA, the desensitization phase for 
F200A showed no significant differences from 
remaining when fit with a bi-
Results 
β2 subunit
β2 required expression 
-response experiments revealed 
ard shift in the curve (Figure 6.2).  Such a change in 
 
 
Figure 6.2  F200A shifts the GABA 
concentration - response curve.  
Responses to a series of GABA 
concentrations were normalized for 
the maximum evoked current.  The 
data was fit with a sigmoidal curve: Y 
= Ymin + (Ymax 
(1+10^((LogEC50 – X)*HillSlope)).  
α1β2-GKER (■) has an EC
F200A (▲) has an EC50
 
 
 
 
receptor gating can be investigated by observing the 
 of GABA.  The macroscopic 
acroscopic desensitization should 
α1β2-GKER for τfast, τslow, τw, or the percent 
exponential equation (Figure 6.3A, Table 6.1).  
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– Ymin) / 
50 of 6 µm.  
 of 800 µm. 
 
  
 
Figure 6.3  F200A drastically accelerates the rate of deactivation, does not alter 
desensitization.  A) Currents evoked from a 500 ms pulse of 30 mM GABA (bar) exhibit similar 
desensitization.  B) Currents evoked from a 
deactivation.  Example responses are ensemble averages of 10
Examination of the macroscopic deactivation can also reveal changes in receptor 
kinetics.  The deactivation waveform is influenced by 
govern the desensitization phase, with the addition of unbinding.  In this case, since there 
was no change in desensitization, any significant change in deactivation is likely to 
represent a change in unbinding.  Interestin
deactivation phase, increasing 
increased unbinding rate. 
 
 
 
 
3 ms pulse of 30 mM GABA (arrow) exhibit distinct 
-30 traces. 
all of the same transitions that 
gly, F200A accelerated the time-course of the 
τw 10-fold (Figure 6.3B, Table 6.1), indicative of an 
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Table 6.1  Summary of parameters from exponential fits of deactivation and desensitization 
Desensitization (500 ms, 30 mM GABA) 
Receptor type τ fast (ms)  τslow (ms)  %τfast %τslow 
% 
Remain 
τ
w 
(ms) n 
α
1
β
2-GKER
 9 ± 3 87 ± 68 63 ± 17 18 ± 12 19 ± 11 22 ± 17 26 
F200A 13 ± 3 85 ± 58 70 ± 11 10 ± 7 20 ± 6 23 ± 14 26 
 
Deactivation (2-4 ms, 30 mM GABA) 
Receptor type τ fast (ms)  τslow (ms)  %τfast %τslow τw (ms) n  
α
1
β
2-GKER
 24 ± 10 281 ± 92 71 ± 8 29 ± 8 96 ± 36 9  
F200A 2 ± 1* 40 ± 27* 94 ± 7* 6 ± 7* 4 ± 1* 10  
 
Parameters are from bi-exponential fits to the desensitization and deactivation waveforms during 
3 ms and 500 ms pulses of 30 mM GABA.  All data are reported as mean ± standard deviation.  
Significant differences between control and mutant parameters were calculated using Student’s t-
test (* p < 0.05). 
 
F200A reduces affinity for the competitive antagonist SR-95531  
Dozens of compounds have been shown to bind in the GABA binding pocket.  
Exploring the effect F200A has on the interaction between any of these compounds and 
the GABAA receptor could clarify the role of F200.  The microscopic kinetics of the 
competitive antagonist SR-95531 were directly measured with a series of antagonist 
unbinding experiments.  In this protocol, outside-out patches were pre-equilibrated in SR-
95531 before jumping into a GABA solution that does not contain SR-95531.  Figure 
6.4A illustrates the response to GABA following pre-equilibration in SR-95531 for α1β2-
GKER and F200A.  The pre-equilibration alters the GABA response because receptors 
bound with SR-95531 during pre-equilibration must first unbind SR-95531 before GABA 
can bind and activate the receptor.  This produces a slowed rise phase mediated by the 
interplay between antagonist unbinding and agonist binding.  
 
 
 
  
Figure 6.4  F200A causes faster unbinding of SR
determined for each receptor type by examining the current response to GABA following a pre
equilibration in SR-95531.  A) Current responses to a control pulse of 30 mM GABA (black 
traces) are overlaid with current responses following pre
GKER) or 100 µM SR-95531 (F200A) (red traces).  B) Plots show the deconvolution of GABA
evoked currents with SR-95531 pre
(red lines) reveal the time course of SR
The current response after pre
unbinding kinetics, but also on the gating and desensitization kinetics of the GABA
receptor.   In order to extract the microscopic antagonist unbinding w
data, the GABA only current must be deconvolved from the pre
(Figure 6.4B).  When these processes are separated by deconvolution, the time course of 
unbinding is revealed.  The deconvolved curve for unbinding was fit 
= [P∞ - (P∞ - P0)e-t/τu]N  , where 
(at t =0) and at steady state (as 
is the time constant of antagonist unbinding 
intercept represents the fraction of receptors unbound after pre
immediately available for activation by GABA.  The microscopic unbinding rate (
-95531.  The koff for SR
-equilibration in 3 µM SR
-equilibration from those without pre-equilibration.  Curve fits 
-95531 unbinding. 
-equilibration relies not only on antagonist 
aveform from this 
-equilibrated current 
by the equation A(t) 
P0 and P∞  are the probabilities of being available initially 
t →∞), N is the number of antagonist binding sites, and 
at each site (Jones et al.,1998).   The y
-equilibration and 
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-
-95531 (α1β2-
-
A 
τu 
-
koff-SR) 
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is equal to 1/τu.  F200A significantly increases the unbinding rate of SR-95531, from 7.3 
± 3 s-1 for α1β2-GKER to 116 ± 32 s-1 for F200A.   
The microscopic affinity constant (KD-SR) was obtained by plotting the fraction of 
receptors unbound at t=0 versus antagonist concentration (Figure 6.5).  The antagonist 
unbinding experiment was repeated with pre-equilibration at several different SR-95531 
concentrations.  This plot was fit with a normalized Hill equation for antagonist.  F200A 
caused a 7-fold increase in KD-SR.   
 
Figure 6.5  F200A shifts the SR-
95531 inhibition curve rightward. 
Dose response curves for the 
equilibrium antagonist occupancy in 
the absence of GABA were fit to the 
normalized hill equation I/Imax = 1 – 
1/[(KD-SR/[SR-95531])N + 1].  α1β2-GKER 
(■, black curve) has a KD of 47 nM.  
F200A (▲, red curve) has a KD of 330 
nM.  
 
 
The microscopic binding rate was directly calculated based on these results using 
the equation kon = koff/KD.  For α1β2-GKER kon = 1.6 ± 0.6 x108 M-1s-1.  For F200A kon = 3.5 
± 0.9 x 108 M-1s-1.  The microscopic binding rate for SR-95531 was increased 2 fold by 
F200A. 
F200A decreases the microscopic binding rate of GABA 20-fold 
The effect F200A has on EC50-GABA and the rate of deactivation suggests that the 
mutation alters GABA affinity.  If this is the case, a considerable reduction in the GABA 
binding rate is also expected.  The GABA binding rate was measured in experiments 
where the competitive antagonist SR-95531 and GABA were simultaneously applied.  
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The current response was diminished relative to a 
control application of GABA, because SR-95531 
competes with GABA for receptor binding sites.  
This response depends on the relative 
concentration and binding rate of each molecule.  
All of these parameters are known, except for the 
GABA binding rate, which can then be calculated.  
F200A elicited a response of 50% when 300µM 
SR-95531 and 30 mM GABA were co-applied.  
This value is termed Irace and is related to the 
binding rates as follows: kon-GABA = [SR95531] kon-
SR/([GABA](1/Irace -1)) (Jones et al., 1998).  The 
GABA binding rate was computed for α1β2-GKER as 
2.7 ± 0.7 x 107 M-1s-1, while F200A kon-GABA equals 
1.3 ± 0.7 x 106 M-1s-1.   
Potential interactions of F200 with arginines in the GABA binding pocket 
F200A has a very similar profile to receptors containing the mutations α1R67A 
and β2R207A, which were previously examined in the Wagner lab.  The effects on EC50, 
deactivation and GABA binding rates are strikingly similar both qualitatively and 
quantitatively.  These residues may simultaneously play independent roles in GABA 
binding; alternatively, GABA binding may require an interaction between F200 and one 
of the arginine residues.  The aromatic phenylalanine and the positively charged arginine 
are able to interact via a cation-π bond.  In order to evaluate if either α1R67 or β2R207 
Figure 6.6  F200A decreases the 
GABA binding rate 20-fold.  Race 
experiments are depicted for α1β2-
GKER and F200A.  For both receptor 
types, currents evoked by 
simultaneous application of 30 mM 
GABA and 300 µM SR-95531 (red 
traces) were compared with the 
current evoked by 30 mM GABA 
alone (black traces).  The two 
separate applications are overlayed 
for each receptor type.  
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interacts with β2F200, double mutants for F200A with R67A, and F200A with R207A 
were expressed.  If there is a specific interaction between the two wild type residues, a 
mutation of just one of the residues to alanine eliminates the bond.  Mutating the other 
residue would have no additional effect since the bond is already eliminated; therefore, 
the double mutant should have very similar kinetics to either single mutant.  If the 
mutations are additive, or completely disruptive, the residues have interactions that are 
not solely dependent on one another and are functionally independent.   
 
Figure 6.7  F200A and R67A 
have additive effects on the 
GABA concentration–response 
curve. Responses to a series of 
GABA concentrations were 
normalized for the maximum 
evoked current. The data was fit 
with a sigmoidal curve: Y = Ymin 
+ (Ymax – Ymin) / 
(1+10^((LogEC50 -X)*HillSlope)).  
α1β2-GKER (■) has an EC50 of 6µm.  
F200A (X) has an EC50 of 800 µm.  
R67A (□) has an EC50 of 1mM.  
The EC50 for F200A/R67A () 
could not be determined. 
 
 
 
When β2-gkerF200A was expressed with α1R67A, GABA activation was only 
observed for concentrations of GABA greater than 1mM.  A complete concentration-
response curve was not established because the maximum GABA concentration used for 
recording did not saturate the GABA response.  The partial curve is shown in Figure 6.7.  
Although an EC50 value cannot be determined for the double mutant, the curve is clearly 
shifted rightward. 
  
In order to demonstrate that the disruption was specific to the GABA binding site, 
GABA responses were compared to responses to propofol, which has a different binding 
site.  Unlike wild-type receptors, in which GABA evoked currents have slightly larger 
amplitudes than those evoked by propofol, the double mutant exhibited a robust propofol 
current and a diminished GABA response (Figure 
activation in the double mutant F200A/R67A indicates that these two residues have 
additive effects and therefore independently contribute to the stabilization the GABA 
interaction. 
Figure 6.8  R67/F200A reduces the potency of GABA relative to propofol.
type and R67A/F200A receptors, current responses were evoked by a 750 ms a
mM GABA (black trace, black bar), followed by a 15 second washout and a 750 ms application 
of 300 µM propofol (red trace, red bar).
 
A full concentration-response curve was obtained for F200A
6.9A).  The double mutant has an 
single, the mutations do not appear to be additive.  Double mutant cycle analysis of the 
EC50 values provided a quantitative assessment of the coupling exhibited by F200 and 
R207 (Figure 6.9B).  A significant coupling energy of 1
suggesting they interact. 
 
6.8).  The severe disruption of GABA 
  For both wild
pplication of 30 
 
/R207A (Figure 
EC50-GABA of 1mM.  Although this is higher than either 
.6 kcal/mol was revealed
99 
-
, 
  
Figure 6.9  F200A and R207A display significant coupling.
GABA concentrations were normalized for the maximum evoked current.  The data was fit 
sgmoidal curve:  Y = Ymin + (Ymax 
(■), F200A (X), R207A (□), F200A.R207A (
on the EC50 values.  ∆∆G = RT ln(mutant EC
2.9 kcal/mol; and ∆∆G1,2 = -3.3 kcal/mol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  A) Responses to a series of 
– Ymin) / (1+10^((LogEC50 – X)*HillSlope)).  
∆).  B) Double mutant cycle analysis was performed 
50/wild-type EC50), ∆∆G1 = -2.0 kcal/mol; 
∆∆Gcoupling = ∆∆G1,2 – (∆∆G1 + ∆∆G2).  
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Discussion 
F200, a novel residue critical to the GABA binding pocket 
Determining the structural significance of a given residue and its relationship to 
receptor function is rarely an easy process, especially without the aid of a high-resolution 
three-dimensional structure.  However, a detailed kinetic analysis of GABAA receptor 
function following a mutation can provide novel information about a particular residue.  
In order to clarify the biophysical role of β2F200 this study aimed to distinguish which 
processes are affected by its mutation and to quantify those effects.  It was previously 
shown that mutation of F200 increases EC50, and it is located at a region (Loop C) that is 
particularly critical for GABA binding.  Presented here is the first evidence of its 
influence on macroscopic deactivation of GABA, the microscopic binding rate of GABA, 
and the binding kinetics of SR-95531. 
When observing macroscopic currents evoked by GABA it became quickly 
apparent that the alanine mutation at position 200 had a major effect.  The major shift in 
EC50-GABA and acceleration of deactivation suggests a large reduction in GABA affinity.  
The EC50 parameter is largely influenced by the KD, and will be shifted rightward by 
increased GABA unbinding rates or decreased GABA binding rates.  Although a 
reduction in channel opening could also shift the EC50 it has been shown that a reduction 
of 90% would be necessary to cause more than a ten-fold shift (Colquhoun 1998).  It is 
highly unlikely that this is the case.  Maximum currents from each patch have a large 
variability, but a reduction of that magnitude would lead to current amplitudes that would 
be too small to analyze.   In addition, the change in deactivation was accompanied by no 
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change in macroscopic desensitization.  This suggests there are no gating changes and 
that the accelerated deactivation is caused by faster unbinding.   
Ultimately, the measurement of the GABA binding rate provides the most direct 
evidence to the effect of F200A.  Indeed, there was a large reduction in the GABA 
binding rate, confirming the importance of this residue in mediating the ligand-receptor 
complex.  The significant increase in unbinding and decrease in binding rates suggests 
that the mutation destabilizes the bound state with GABA, which results in a dramatic 
reduction in GABA affinity.  F200 fits the profile of a residue that could directly interact 
with GABA.    
Relating structure to function 
The phenylalanine side-chain consists of a short one-carbon chain connected to an 
aromatic ring making the side-chain large and hydrophobic.  Also, the aromatic ring has 
an electronegative potential on its planar surfaces, which is capable of forming 
electrostatic interactions via a cation-π bond.  Such a bond could potentially stabilize the 
amine group of GABA.  A cation-π interaction with GABA has previously been proposed 
for β2Y97 (Padgett et al., 2007), yet has never been considered for F200.    
F200 has not previously been postulated to directly interact with GABA because 
SCAM surveys of the region found no detectable effect on GABA responses when 
β2F200C or nearby residues were reacted with a MTS reagent (Wagner and Czajkowski, 
2001).  It was concluded that this region was likely buried in the hydrophobic core of the 
subunit, but it was also acknowledged that these residues may react with a MTS reagent 
without affecting the GABA response.  The evidence here demonstrates that F200 plays a 
critical role at the binding site.  F200 could be situated in a location that was not 
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accessible to the large MTSEA-biotin reagent used in the SCAM study, but is still 
accessible to the smaller GABA molecule.  Alternatively, F200 could be inaccessible to 
both and mediate GABA binding indirectly. 
A cation-π interaction could also occur between F200 and a positively charged 
residue in the GABA binding pocket.  Analysis of two potential candidates (R67 and 
R207) only revealed a strong coupling energy between F200 and R207.  The mutant-
cycle analysis result from the two alanine mutations of these residues cannot distinguish 
if coupling arises from a direct or indirect interaction.  The use of a side-chain swap was 
able to substantiate a direct interaction.  The constructs F200R, and F200R/R207F were 
generated as part of this investigation, but were later fully analyzed during a separate 
project in the Wagner lab.  Not only are the effects of F200R/R207F non-additive, but the 
double mutant partially rescues the effects of either single swap (P. Tran, unpublished 
data).  This result may represent a restoration of a direct interaction between the residues 
at position 200 and 207.  The significance of the R207-F200 interaction could be 
necessary to position F200 in the optimal position to stabilize GABA.  Considering that 
the single F200A mutant is even more disruptive than R207A, F200 is likely located in 
closer proximity to the site of GABA binding.  F200 may participate with the previously 
identified Y97 to stabilize the amino group of GABA.  
The structural significance for F200, and its interaction with R207, may 
alternately be rooted in its location and influence on Loop C.  This dynamic loop is 
expected to move during GABA binding.  Comparison of crystal structures of AChBP 
bound with ligand or bound with HEPES indicated that loop C contracts around the 
ligand (Celie et al., 2004).  In the GABAA receptor, movement of Loop C during receptor 
104 
 
 
activation was demonstrated using SCAM experiments (Wagner and Czajkowski, 2001).  
Furthermore, the mobility of loop C appears to be greater in the resting state of the 
GABAA receptor than in the activated state.  Experiments using a pair of cysteine 
mutations at K196 of Loop C and the closely situated E153 found that disulfide formation 
was restricted in the presence of GABA or pentobarbital (Venkatachalan and Czajkowski, 
2008).  The flexibility of Loop C when the GABAA receptor is unbound may allow the 
ligand access to the binding pocket, and the closure of Loop C during ligand binding may 
stabilize the ligand-receptor complex as well as be integral to receptor activation.  The 
mutation of F200 could disrupt Loop C’s mobility and interfere with the region’s ability 
to facilitate binding.  The results here clearly demonstrate that F200A leaves the binding 
pocket in a non-ideal conformation that not only decreases the ability of GABA to bind, 
but also allows GABA to fall off more easily.  Whether F200 directly interacts with 
GABA or supports the local architecture of the binding site, the dramatic effects F200A 
have on GABA kinetics suggest it is close to a critical position that mediates GABA 
binding. 
F200 stabilizes the bound state for SR-95531 
The changes in SR-95531 affinity also bear significance because the structure of 
SR-95531 contains a GABA-like region and binds in the GABA binding pocket.  F200A 
predominantly altered KD-SR by increasing the koff-SR.  The significant increase in the koff 
(while kon is relatively unchanged) suggests that aromatic side-chain is necessary for 
stabilizing the SR-95531-receptor complex, but does not contribute a direct interaction 
that facilitates binding.  Conceivably, F200 provides stability via hydrophobic 
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interactions between the aromatic ring of F200 and the ring structure of SR-95531.  This 
of course would require that the F200 side-chain contribute to the binding pocket. 
Mutation of F200 to alanine specifically alters GABA binding and unbinding 
processes, without affecting desensitization.  Furthermore it significantly alters the free 
energy of the bound state of the receptor with SR-95531, indicating F200 is in the 
binding pocket.  The precise role of F200 is not yet clear, but these results make it a 
candidate for one of the primary residues that directly mediate GABA binding. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
 
 
 
 
 
 
 
 
 
 
 
 
VII.  IDENTIFICATION OF AMINO ACID RESIDUES 
 THAT DICTATE SELECTIVE ASSEMBLY OF 
GABAA RECEPTOR SUBUNITS 
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Introduction 
Depending on their subunit composition, GABAA receptors exhibit distinct 
pharmacological and electrophysiological properties; however, the extent of receptor 
diversity in vivo is unknown.  Although nineteen GABAA receptor subunits have been 
identified, providing the potential to form a vast number of distinct receptors, only a 
limited number of combinations (approximately 25) are thought to exist
 
in vivo 
(Mizielinska et al., 2006).  Considering the fact that multiple subunits from different 
classes (i.e. α, β, γ, δ) and within the same class (i.e. α1, α2, α3) can be expressed at the 
same time in a single neuron, additional mechanisms must exist to control receptor 
biogenesis (Whiting, 2003).  In order to have a clear picture of receptor diversity and the 
subsequent pharmacology, it is important to understand the processes that dictate subunit 
assembly.   
The determinants for assembly of α, β, and γ subunits have been explored most 
frequently because receptors containing α, β, and γ subunits are the most common in the 
brain (Mohler, 2006).  Several independent studies have established these subunits are 
capable of forming receptors composed of two α, two β, and one γ subunit, or two α and 
three β subunits (Tretter et al., 1997, Farrar et al., 1999, Bauman et al., 2001; Bauman et 
al., 2002).  In addition, these studies have suggested the specific subunit arrangements of 
these receptors are βαβαγ or βαβαβ, forming five inter-subunit interfaces: β(+)/α(-), 
α(+)/β(-), β(+)/α(-), α(+)/γ or β(-), and γ or β(+)/β(-) (Figure 7.1).   
The key to understanding receptor diversity is the identification of the assembly 
signals that govern which subunits prefer to be positioned next to each other.  This has  
 
  
 
Figure 7.1  GABAA receptor subunit arrangement.
of 2α1, 2β2, and a fifth subunit that is either 
labeled.  These subunits have been shown to assemble with a counter
α, β, α, and γ/β.  The GABA binding si
and the location of the mutations studied here are denoted by a star.
 
been studied using fluorescent microscopy
subunits, as well as with co-immun
determinants of specific oligomerization patterns have been exploited using these 
techniques along with the comparison of v
chimeric isoforms, and site-directed mutagenesis.  
GABAA receptor subunits was identified in the cytoplasmic loop between transmembrane 
domains 3 and 4 (Lo et al., 2008)
found in the N-terminal extracellular domain.  Many of these signals lie at or near 
predicted subunit interfaces.  
At the α(+)/γ(-) inter-
have been shown to mediate 
demonstrated between these specific regions 
2001).  On the other face of the 
  Depicted is a GABAA receptor composed 
γ2 or β2.  The (+) and (-) face of each subunit is 
-clockwise orientation of 
tes, at the β/α interfaces, are indicated by black triangles, 
 
 to follow surface expression of epitope tagged 
oprecipitation experiments and western blots.
arious subunit isoforms, construction of 
A region required for assembly of all 
; however, the majority of assembly signals have been 
 
subunit interface the sequences α1(80-100) and 
assembly of these subunits, and a direct interaction has been 
(Klausberger et al., 2000; Klausberger et al., 
γ2 subunit, residues 83-90 have been shown to mediate 
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β, 
  The  
γ2(91-104) 
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assembly of γ2 with β3 subunits (Klausberger et al., 2000).  At the equivalent interface in 
receptors containing β2, the epilepsy mutation γ2R43Q has been shown to disrupt 
assembly of functional receptors (Hales et al., 2005).  Residues 58-67 on α1 are important 
for assembly with a β subunit at the GABA binding site interface (Taylor et al., 2000; 
Bollan et al., 2003).  At the α(+)/β(-) inter-subunit interface (non-GABA binding) β3(76-
89) and α1A108 are critical for assembly of functional receptors (Ehya et al., 2003; Sarto-
Jackson et al., 2006). 
The assembly signals for β2 have not been as well studied.  Several mutations on 
β2 at the GABA binding site abolish GABAA receptor function (Amin and Weiss, 1993), 
suggesting a role for such residues in assembly of the β(+)/α(-) inter-subunit interface; 
however it has not been verified if these mutations alter translation of the subunit, the 
subunits fail to completely oligomerize, fully assembled receptors are not properly 
transported to the cell surface, or if non-functional receptors reach the cell surface.  
Therefore it is not known if such β2 residues dictate assembly with specific subunits.  
The scanning alanine mutagenesis study presented in Chapter III identified three 
mutations of the β2 subunit (Y97A, Y157A, and D163A) that lead to interesting 
expression profiles and may play an important role in assembly of GABAA receptors.  
Mutation of these residues allowed the assembly of functional receptors when expressed 
with α1 and γ2, but not when expressed with α1 only.  αβ receptors are believed to contain 
three β subunits, while αβγ receptors only contain two (the third being replaced by γ).  
Because of this a β(+)/β(-) interface exists in αβ receptors, but a γ(+)/β(-) interface exists 
in αβγ receptors.  Our result suggests these residues are required in assembly of the 
β(+)/β(-) interface, critical for GABAA receptors composed of βαβαβ subunits, but not 
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βαβαγ subunits.  Here we show that the lack of functional expression for these mutants is 
the consequence of reduced surface expression.  Furthermore, the corresponding residues 
on the γ2 subunit were mutated and characterized.  The results suggest that β2Y97 is a 
general determinant of assembly for multiple classes of GABAA receptor subunits, while 
β2Y157 has a specific role in assembly of the β(+)/β(-) interface.  
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Results 
Electrophysiological expression profiles are altered by mutations at the (+) face of β2 
The residues Y97, Y157, and D163 of the β2 subunit were mutated to alanine, and 
the mutant constructs were separately transfected with the α1 construct in HEK-293 cells.  
GABA application (10-100 mM) to outside-out patches pulled from these cells rarely 
evoked currents (Table 7.1, Figure 7.2).  Propofol (100 µM – 300 µM) also failed to 
evoke current with patches pulled from these cells (Figure 7.3).  Interestingly, when these 
mutants were expressed with α1 and γ2, GABA application consistently evoked a current 
response (Table 7.1, Figure 7.2).  However, the average maximum current amplitude 
during GABA application to each patch was diminished for all of the mutants.  These 
results indicate that the three β mutations do not prevent oligomerization of the β(+)/α(-) 
interface, which is the site of GABA binding.  These mutations may be interfering with 
assembly of a β(+)/β(-) interface, but are not relevant to a γ(+)/β(-) interface.  
Table 7.1  Electrophysiology characterization of the expression of β2 mutants 
Receptor Type Total patches 
Patches with GABA 
current* 
% Patches with 
current 
Average 
Maximum 
Amplitude (pA)† 
α1β2 5 5 100 88 
α1β2D163A 13 2 15 6 
α1β2Y97A 8 0 0 0 
α1β2Y157A 16 3 19 11 
α1β2γ2 12 12 100 580 
α1β2D163Aγ2 10 9 90 164 
α1β2Y97Aγ2 9 8 89 39 
α1β2Y157Aγ2 12 12 100 175 
   
 
 *  Only responses >5 pA were counted.  † Measured as the peak current response of a single 
pulse of GABA (10 – 100 mM).  Average includes only patches with current. 
 
 
  
 
 
Figure 7.2  GABA
responses from 
αβγ receptors containing 
mutant β
Currents evoked from
ms application of GABA 
(black bar) to patches 
pulled from HEK
expressing control and 
mutant receptor types.  
GABA concentrations 
between 30 mM and 100 
mM were used as 
indicated. 
 
 
 
Figure 7.3  
responses from 
αβγ receptors con
mutant β
Currents evoked from 500 
ms application of 300 
propofol (black bar) to 
patches pulled from HEK
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Surface Expression of α1β2-Halo receptors and α1β2-Haloγ2 receptors  
In order to clarify the impact each mutation has on GABAA receptor biogenesis 
and function, the cell surface expression of receptors was assessed.  This was 
accomplished using a Halotag® (Promega), which has been commercially designed with 
various fluorescent ligands that are highly specific and are either cell permeable or cell 
impermeable.  A Halotag®-β2 fusion protein was generated, placing the Halotag® 
between the 4th and 5th amino acids of the mature protein sequence.  Although the 
Halotag® is a large domain (400 amino acids), it has previously been shown that the 
Halotag® is well tolerated and does not interfere with assembly, cell surface trafficking, 
or GABAA receptor pharmacology or function when incorporated into the γ2 subunit (Los 
and Wood, 2007).  Whether the Halotag® influences receptor function when placed on 
the β2 subunit was not known; therefore, electrophysiological expression experiments 
were repeated for each receptor type.  Responses of outside-out patches with α1β2-Haloγ2 
receptors to GABA application were indistinguishable from α1β2γ2 receptors when 
comparing current amplitude and EC50-GABA.  The Halotag® did not alter the expression 
profile of β2-HaloY97A or β2-HaloY157A; however, β2-HaloD163A could no longer respond 
to GABA  when expressed with α1 and γ2.  This prevented further characterization of the 
effects of D163A on receptor assembly. 
Labeling and fluorescent microscopy was performed using HEK-293 cells that 
had been plated onto poly-lysine coated glass coverslips and incubated in 24-well plates.  
40-50 hours post-transfection, the cells were labeled first with the cell-impermeant 
AlexaFluor 488 ligand (494ex/517em).  This ligand bound the receptors on the cell 
surface.  This was followed by labeling with the cell-permeant TMR ligand 
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(555ex/585em), which labeled the intracellular Halo-tagged subunits.  The surface and 
intracellular labels were simultaneously observed using confocal microscopy and laser 
excitation at 494 (for the Alexafluor ligand) and 555 (for the TMR ligand).  α1β2-Halo and 
α1β2-Haloγ2 receptors exhibited pronounced surface labeling (Figure 7.4).  Expression of 
β2-Halo alone exhibited no surface labeling.  This is in agreement with previous reports of 
the β2 subunit not being able to reach the cell surface without being assembled into a 
pentamer with α subunits and/or other isoforms (Connolly et al., 1996).  
In agreement with the electrophysiology results, both β2-HaloY97A and β2-
HaloY157A exhibited only intracellular labeling when expressed with α1 (Figure 7.4A).  
These results were quantitatively assessed by comparing the percent surface label for 
individual cells.  Both α1β2-HaloY97A and α1β2-HaloY157A demonstrated significantly 
reduced surface expression compared to wild-type α1β2-Halo, and were indistinguishable 
from the negative control (Figure 7.4C).  The reduction in surface expression confirmed 
that the lack of electrophysiological responses for αβ receptors with these mutations was 
the consequence of disrupted assembly or trafficking. 
When expressed with α1 and γ2, β2-HaloY157A demonstrated visible surface 
expression (Figure 7.4B).  Quantitatively, the percent surface expression was not 
different from the positive control (Figure 7.4D).  β2-HaloY97A, however, exhibited 
reduced surface labeling when expressed with α1 and γ2 (Figure 7.4B).  Quantitatively, 
the percent surface expression for α1β2-HaloY97Aγ2 was significantly reduced compared to 
wild-type receptors, but was still greater than the negative control (Figure 7.4D).   
 
 
  
 
Figure 7.4  Surface expression of 
Expression of Halo-tagged subunits was determined by labeling with a cell
Alexafluor 488 ligand, followed by labeling with a cell
transfection, and images were collected by confocal microscopy.  The scale bars
A)  Combinations of α1 and mutant 
Y157A represent expression of 
Combination of α1,  mutant β2
Y157A’ represent expression of 
(C and D) The percent of surface expression was quantified by measuring the mean intensity of 
the AlexaFluor 488 label relative to the total of AlexaFluor 488 label plus TMR label mean 
intensity of individual cells.  The percent surface expression is normalized to C) the wild
α1β2-Halo receptor or D) the wild
compared to the wild-type receptor and † denotes significant difference when compared to the 
negative control (β2-Halo only), Student’s t
page.  
α1β2-Halo receptors and α1β2-Haloγ2 receptors.  
-permeable TMR ligand 60 hours after 
 represent 40 
β2-Halo subunits were examined.  Rows labeled Y97A and 
α1β2-HaloY97A and α1β2-HaloY157A receptors, respectively.  
-Halo, and γ2 subunits were examined.  Rows labeled Y97A’ and 
α1β2-HaloY97Aγ2 and α1β2-HaloY157Aγ2 receptors, respectively.   
-type α1β2-Haloγ2 receptor.  * Denotes significant di
-test (p < 0.05).  Panels B, C, and D continued on next 
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Mutation and expression of conserved residues on the γ2 subunit     
Both β2Y97 and β2Y157 are highly conserved across cys-loop LGIC subunits, and 
the corresponding residues on the γ2 subunit were also investigated to determine if the 
same signals that are important to assembly of the β(+)/β(-) inter-subunit interface are 
also important for the γ(+)/β(-) inter-subunit interface.  β2Y97 aligns with γ2F112, and 
β2Y157 aligns with γ2Y172.  A Halotag®-γ2 fusion protein was generated in order to 
specifically assess the incorporation of this subunit when the corresponding mutations are 
added.  Expression of either γ2-HaloF112A or γ2-HaloY172A with α1 and β2 yielded GABA 
evoked currents that appear to be the result of receptors containing α, β, and γ subunits, 
not αβ receptors (Figure 7.5).  These currents demonstrated a peak response to 100 µM 
GABA that was 60% of the peak response to 100 mM GABA, similar to α1β2γ2 receptors 
which have an EC50-GABA of 70 µM and also demonstrate a 60% response of 100 µM to 
100 mM GABA.  This suggests the γ2-Halo subunit is being incorporated into these 
receptors because receptors composed of α1β2, which have an EC50-GABA of 6 µM, show a 
90% response with 100 µM GABA compared to 100 mM GABA.  Also, the average 
maximum current amplitude was 200 pA for α1β2γ2-Halo receptors, which is much larger 
than normally seen for α1β2 receptors.  Both characteristics support that these responses 
are from γ2 containing receptors.  When these mutants were combined with the 
corresponding mutation of the β2 residue, neither α1β2Y97Aγ2-HaloF112A nor 
α1β2Y157Aγ2-HaloY172A exhibit current response to GABA. 
To test whether the γ2 mutations reduced the surface expression of receptors, 
labeling and fluorescence microscopy was performed.  α1β2γ2-HaloY172A demonstrated 
substantial γ2-Halo localization at the cell surface (Figure 7.6A).  The percent surface 
  
expression for α1β2γ2-HaloY172A 
(Figure 7.6B).  α1β2γ2-HaloF112A 
wild-type receptors (Figure 7.6A and B).  Combination of the 
β2Y97A completely abolished surface expression, whereas combination of 
and β2Y157A still exhibited the equivalent surface expression as wild
The corresponding residues γ
where as β2Y157 plays a unique role in assembly of 
the corresponding residue γ2Y172
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Figure 7.6  Surface expression of 
was determined by labeling with a cell
with a cell-permeable TMR ligand 60 hours after transfection, and images were collected by 
confocal microscopy.  Row labe
represents α1β2Y97Aγ2-HaloF112A, Y172A represents 
represents α1β2Y157Aγ2-HaloY172A receptors.  B) The percent of surface expression was 
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page.  
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Discussion 
Specific assembly signals between subunits exist that are critical for accurate 
receptor biogenesis.  Three residues on the β2 subunit (Y97, Y157, and D163) that may 
serve as assembly signals were investigated.  When each of these residues was mutated to 
alanine, the β2 mutant subunit was unable to form functional receptors with α1.  However, 
when the β2 mutants were expressed with α1 and γ2, robust GABA evoked currents were 
observed.  This implies that these residues are not obligatory for cell-surface expression 
of GABAA receptors, but influence specific receptor stoichiometries.  These mutations 
allow the successful assembly of the β(+)/α(-) interface (as it is necessary for GABA 
binding) and likely interfere with the assembly of a third β subunit, which forms the 
β(+)/β(-) interface (Figure 7.1).   
Y97 and Y157 have distinct influences over surface expression of αβ and αβγ receptors 
The absence of surface labeling when β2Y97A or β2Y157A is expressed with α1 
verifies that the lack of current responses to GABA or propofol is the result of disrupted 
assembly or trafficking of the receptor.  The disruption of assembly by these residues 
would likely manifest at the β(+)/α(-) interface (the GABA-binding site) or the β(+)/β(-) 
interface, where they are present.  A β(+)/β(-) interface only exists when expressing α and 
β, not when expressing α, β, and γ (Tretter et al., 1997, Farrar et al., 1999, Bauman et al., 
2001; Bauman et al., 2002).  Therefore, if such residues mediate assembly specifically of 
the β(+)/β(-) interface, cell-surface expression would be impaired when expressing α and 
β, but not when expressing α, β, and γ.  This is exactly what we observed. 
When β2Y97A or β2Y157A is expressed with α1 and γ2, both allow the functional 
expression of receptors that can elicit GABA-evoked currents.  Also, both demonstrate a 
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reduction in the average current amplitude relative to wild-type receptors.  Based on 
surface labeling results, the current reduction associated with β2Y97A when expressed 
with α1 and γ2 is in part the consequence of decreased receptors at the cell membrane.  
The sensitivity of assembly to mutation at β2Y97 suggests that the residue plays a general 
role in assembly of receptors.  While it is absolutely disruptive to formation of αβ 
receptors, it partially disrupts the formation αβγ receptors.  Therefore, β2Y97 is not only 
important for assembly of a β(+)/β(-) interface, because no β(+)/β(-) interface exists in 
the αβγ receptor.  The complete failure of assembly for αβ receptors may not be due 
solely to disruption of a β(+)/β(-) interface, but may arise due to an accumulation of 
disturbances at three interfaces, the β(+)/β(-) interface and both β(+)/α(-) interfaces.  Such 
disturbances of inter-subunit interactions could lead to an altered quaternary subunit 
positioning, making incorporation of the last subunit more fragile.   
There is no reduction in surface labeling when β2Y157A is expressed with α1 and 
γ2, suggesting the observed reduction in current amplitude is attributable to a change in 
receptor function.  The large shift in the concentration-response curve, with an EC50-GABA 
greater than 30 mM, supports that this is the result of decreased GABA affinity.  The 
normal expression of α1β2-HaloY157Aγ2 indicates that β2Y157 is specifically important for 
the assembly of a β(+)/β(-) interface, not a γ(+)/β(-) interface.  β2Y157 is located at the 
(+) face of the β2 subunit and not expected to directly influence the γ(+)/β(-) interface.  
β2Y157 is also at the β(+)/α(-), but the results here suggests that it is not a major 
assembly determinant of this interface.  
Although the electrophysiological expression profile for β2D163A containing 
receptors was similar to the other mutations, changes in surface expression could not be 
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verified because β2D163A does not tolerate the Halotag®.  The reduction in average 
maximum current amplitude for α1β2D163Aγ2 receptors compared to α1β2γ2 receptors 
may reflect a partial disruption of assembly, even in the presence of γ2.  Unlike β2Y157A, 
β2D163A caused only a mild 2-fold shift in the EC50-GABA (Chapter III).  Also, β2D163A 
does not change the single channel conductance of αβγ receptors when on a β2-GKER 
background (Chapter V).   Therefore the reduced current amplitude is more likely 
because of fewer receptors being present at the cell surface.  In this regard, β2D163A 
appears more similar to β2Y97A than β2Y157A. 
Conserved residues do not always have completely conserved roles 
These residues are highly conserved amongst human GABAA receptor subunits: 
α1(F100, Y160), β2(Y97, Y157), and γ2(F112, Y172) (Chapter I, Figure 1.7) .  Whether 
either residue serves as an assembly signal for the γ2 subunit at the γ(+)/β(-) interface was 
investigated with the mutations γ2F112A and γ2Y172A.  Although a GABA-evoked 
response was observed when expressing γ2-HaloF112A with β2 and α1, reduced surface 
labeling indicates incorporation of γ2 was hindered.  The observed current reduction may 
result from only αβ receptors, which have a lower single channel conductance than αβγ 
receptors (Fisher and Macdonald, 1997; Jahn et al., 1997), being properly assembled and 
trafficked to the cell surface, or may be the result of a reduced number of αβγ receptors at 
the cell surface.  It therefore appears β2Y97 and γ2F112 have a conserved role in 
assembly.  The reduced surface expression of β2Y97A in αβ receptors and γ2F112A in 
αβγ receptors suggest this residue is required for oligomerization of a β(+)/β(-) interface, 
as well as a γ(+)/β(-) interface.  The lack of surface labeling when α1β2Y97Aγ2-HaloF112A 
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is expressed further suggests a compounding effect when the mutation is present at three 
interfaces. 
Uniquely, β2Y157A only disrupts the assembly of the β(+)/β(-) interface.  
Mutation of the corresponding residue γ2Y172 does not alter surface expression.  When 
γ2-HaloY172A is expressed with β2 and α1 or with β2Y157A and α1, γ2-HaloY172A reaches 
the cell membrane as robustly as wild-type γ2-Halo.  γ2 does not reach the cell membrane 
by itself when expressed with α and β subunits (Connolly et al., 1999; Los and Woods, 
2007); therefore, it is assumed that surface expression of γ2 represents intact receptors at 
the cell surface.  γ2Y172A is able to restore the surface expression of receptors with 
β2Y157A, suggesting γ2Y172 does not play the same role in assembly as β2Y157.  
  The absence of GABA current when expressing β2Y157A, γ2-HaloY172A, and α1 
subunits further demonstrates the significance of this tyrosine for GABA mediated 
events.  Additionally, the receptor function of the β2Y157A/γ2Y172A could be explored 
using alternative receptor agonists, such as propofol. Although it was a very small sample 
size, the lack of current may suggest a severe disruption of GABA binding site, or 
receptor activation overall.  
Residues at the subunit interface influence assembly 
Residues that are positioned on a subunit so they face an inter-subunit interface 
are in an ideal location to mediate protein-protein interactions.  SCAM experiments 
demonstrated that β2Y97, β2Y157, and β2D163 face the aqueous environment at the 
GABA binding pocket (Boileau et al., 1999; Newell et al., 2004).    These residues may 
mediate assembly via direct interaction with residues on the opposing subunit.  There 
could be an electrostatic interaction for D163 (perhaps with R120 or another positive 
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residue during the oligomerization process).  The aromatics may provide stabilization at 
an inter-subunit interface by stacking with other aromatic side-chains in a π-π interaction, 
or by participating in a cation-π interaction with a basic residue (Burley and Petsko, 
1985).  Also, the hydrophobic nature of the aromatic side-chains could influence 
assembly because covering them with the adjacent subunit will minimize the number of 
hydrophobic side-chains exposed to water and stabilize the protein conformation. 
A final word on GABAA receptor stoichiometry 
The ability of γ2 to rescue (at least to some extent) the mutations of β2D163, 
β2Y97, and β2Y157 adds strong support to the stoichiometry of αβ receptors consisting of  
two α and three β subunits.  The stoichiometry of αβ receptors is particularly relevant to 
the work of our lab, which has relied heavily on the expression of αβ receptors.  Although 
several studies have concluded this same ratio, there still exists debate about whether a 
third α might actually complete the pentamer.  This originates from studies expressing α-
β concatenated subunits that found only the addition of a single α subunit could result in 
GABA activated channels (Im et al., 1995; Boileau et al., 2005).  This expression may be 
a consequence of the tandem construct, which relied on 10x-glutamine linkers between 
the two subunits.  The positioning between the tandem subunits may not represent the 
normal orientation, and allow for unnatural receptor combinations to form that are 
otherwise unfavorable.   It is clear that two α and two β subunits are required to form the 
GABA binding sites, but it is not intuitively obvious what the fifth subunit must be.  The 
ability of γ to replace the fifth subunit and rescue assembly of these mutants is much 
more plausible if the fifth subunit is β.  In this scenario, the γ containing receptor now has 
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only two mutated β subunits instead of three.  Considering the dosage-like dependence of 
β2Y97A expression, two α and three β is most likely the correct stoichiometry.   
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VIII.  Conclusion 
 The studies performed in this dissertation were designed to refine our knowledge 
about the architecture of the GABA binding pocket of the GABAA receptor.  A clear 
description of the structure, including inter-subunit interactions, intra-subunit interactions 
and interactions with GABA that exist in the binding pocket, is necessary to build a 
complete biophysical description of receptor function.  This was not an entirely novel 
endeavor.  For decades researchers have been trying to elucidate the structures of LGICs 
and identify the locations of binding for various ligands.  A variety of site-directed 
mutagenesis studies and photoaffinity labeling studies had firmly placed the GABA 
binding pocket at the inter-subunit interfaces between β and α subunits.  A picture of the 
GABA binding pocket started to evolve with the help of secondary structure prediction 
from the protein sequence.  Homology modeling of the GABAA receptor has provided a 
putative three-dimensional framework of the binding pocket.  Also, SCAM studies have 
surveyed the six discontinuous loops surrounding the binding pocket.  The SCAM studies 
have indicated specific residues that face the binding pocket, the secondary structure of 
each loop, and the mobility of each loop. 
 Despite these advances, the specific interactions that mediate GABA binding are 
unknown.  Using the earlier evidence as a guide and starting point, our lab set out to 
identify important structural components of the binding pocket.  A multitude of results 
from this dissertation provide evidence of specific side-chain interactions, and they 
suggest certain residues that are most likely to contribute to the binding of GABA and 
stabilization of the bound state. 
 
  
Homing in on the location of GABA
 SCAM results suggested which residues 
exists at the inter-subunit interface and represents the GABA binding pocket (Figure 
8.1A) (Boileau et al., 1999; Wagner et al., 2001; Boileau et al., 2002
2003;Newell et al., 2004; Kloda et al., 2
the potential players in the binding pocket, but offered little indication of the precise 
location of GABA when bound.  More discerning SCAM experiments, conducted as part 
of the same studies, identified seve
GABA and SR-95531 compounds (Figure 8.1B).  Protection may result from steric block 
of the MTS reagent by the ligand or from a conformational rearrangement induced by the 
ligand, but these two compounds
changes.  The residues that are protected by both compounds begin to paint a clearer 
picture of the sub-region of the pocket that facilitates binding.  The residues are 
Figure 8.1  SCAM experiments provi
residues on each of the six discontinuous loops of the binding pocket that were found to face the 
aqueous environment are shown with space
are protected from MTS reaction by both GABA and SR
closer to the center of the binding pocket.  C)  Two residues (
protected by GABA, but were protected by the larger SR
positions are removed from the site of a bound GABA compound.
 
 in the binding pocket 
were likely to face the aqueous space that 
; Newell et al., 
007).  These results provided major evidence of 
ral residues that were protected from MTS reaction by 
 are not expected to induce the same conformational 
ded an outline of the GABA binding pocket.  
-filled van der Waals surfaces.  B) The residues that 
-95531 are depicted and are clustered 
α1R120 and α1D63) were not 
-95531 compound, suggesting their 
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concentrated "behind" Loop C, and mainly include contributions from Loop A, Loop B, 
Loop C, and Loop E.  This sub-region was a primary focus of the studies here, and it is 
interesting to consider how mutations of these residues have diverse effects on receptor 
kinetics. 
Mutational studies have examined most of these residues previously in a variety 
of expression systems, with various subunit combinations, and with various side-chain 
substitutions.  This dissertation presented a methodical characterization of these residues 
and included a detailed analysis of macroscopic kinetics of the deactivation and 
desensitization phases.   Additionally, β2R207, α1R132 and α1R67 were analyzed in a 
parallel study performed in the Wagner lab.  The most dramatic shifts in the EC50 were 
observed for β2Y97A, β2F200A, β2T202A, β2Y205A, β2R207A, α1R67A (Figure 8.2A).  
The large shifts were consistent with previous concentration-response studies (Amin and 
Weiss, 1993; Boileau et al., 2002; Wagner and Czajkowski, 2001; Holden and 
Czajkowski, 2002).   A dramatic change in EC50 does not imply a direct interaction with 
GABA; furthermore, it may not even be the result of changes in GABA affinity, as 
decreases in efficacy can also shift the concentration-response curve rightward.  In order 
to separate residues that mediate GABA affinity from those that may provide a link in the 
transduction mechanism of the receptor, it was necessary to characterize how each 
residue impacts specific aspects of receptor function (binding, unbinding, desensitization, 
or channel opening). 
At minimum, examination of the effect each mutation had on the macroscopic 
kinetics of the GABAA receptor was able to identify residues that influence macroscopic 
desensitization and/or deactivation kinetics.  In cases where macroscopic desensitization 
  
was unaltered, but macroscopic deactivation was affected, we can infer changes in the 
unbinding rate of GABA.  In figure 8.2B, mutations that cause the most sign
acceleration of the macroscopic deactivation phase are shown.  It is not possible to make 
a distinction from a residue that directly interacts with GABA or one that indirectly 
influences the stability of a bound GABA compound.  However, it is expec
mutation of a residue that directly interacts with GABA will adversely affect the stability 
of the ligand-receptor complex.  Therefore, these residues are all plausible candidates for 
mediating GABA binding.   
Mutation of a residue that directly 
decrease the GABA binding rate.  Although fewer residues have been examined, the two 
residues with the most dramatic reduction in GABA binding when mutated to alanine are 
β2F200 and α1R67 (Figure 8.2C).  Both 
pocket, where the majority of the residues that severely impact EC
deactivation are also found.  
Figure 8.2  Alanine mutation of only a few residues caused dramatic shifts in EC
rate of deactivation, and the microscopic GABA binding rate.  Therefore the bound GABA 
compound is most likely located at this precise region of the binding pocket.  
increases in EC50-GABA were observed for 
B)  The most significant accelerations of the deactivation rate were observed for
α1R120A, β2Y157A, β2F200A, and 
observed for α1R67A and β2F200A.
ificant 
ted that 
interacts with GABA is also expected to 
residues are located in the middle of the binding 
50-GABA and 
A)  The largest 
α1R67A, β2Y97A, β2Y157A, β2F200A, and 
β2R207A.  C) The most significant decreases in 
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The mechanisms of desensitization are also poorly understood.  Although all 
evidence suggests desensitization primarily occurs only when GABA is bound (Burkat et 
al., 2001), no direct connection between a binding pocket residue and desensitization had 
been identified previously.  Here, two residues (α1R120 and α1L128) altered the 
desensitization phase when mutated to alanine.  Both are located on Loop E, which may 
represent a structural element that is critical to desensitization.   
It is difficult with the methodology employed by our lab to confirm direct 
interactions between binding pocket residues and a ligand.  However, supporting 
information is beginning to accumulate, and the array of effects observed when each 
residue is mutated allows us to distinguish the residues that have a critical role in the 
binding or stabilization of GABA from those residues that are less influential.  The sub-
region of the binding pocket containing β2F200 and α1R67 offers the most plausible 
location for GABA.  Several residues in the vicinity of β2F200 and α1R67 have similar 
and significant effects on EC50 and deactivation, plus they were protected by GABA 
during SCAM experiments.   
Residues that demonstrate a mild effect on EC50 and deactivation when mutated to 
alanine, are less likely to mediate GABA binding.  For example, α1R120A shifts EC50 
and deactivation, but to a lesser extent than β2F200A or α1R67.  α1R120 is not expected 
to directly interact with GABA and  appropriately it is found in a more distal region of 
the binding pocket.   Residues such as α1R120 and α1D63 were not protected by GABA 
during SCAM experiments, further indicating they are removed the site of the bound 
GABA compound (Figure 8.1C). Remember, these interpretations are being made in the 
context of the current homology model, which itself is not certain.  It is reasonable to 
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believe that the position of each loop represents a close approximation (Cromer et al., 
2002), but we must acknowledge that our interpretations are not yet definitive. 
Model for GABA binding 
GABA has a zwitter-ion chemistry with a positive amino end and a negative 
carboxy end.  Its binding is likely to be mediated via electrostatic interactions at each 
end.  I hypothesize that GABA forms direct interactions with β2F200 and α1R67 (Figure 
8.3).  These two residues show the largest reductions in binding rate and the largest 
increases in the deactivation rate or unbinding rate.  The hypothesized binding of GABA 
entails β2F200 forming a cation-π bond with the amino end of GABA and α1R67 forming 
an electrostatic interaction with the negative carboxy end.  β2Y97 may also contribute to 
the stabilization of the amino end of GABA.  Detailed analysis of the chemistry of β2Y97 
using unnatural amino-acid substitution demonstrated that it participates in a cation-π 
bond (Padgett et al., 2007).  Here we observed that mutation of β2Y97 to alanine  
caused an increase in EC50-GABA, accelerated deactivation, and decreased the GABA 
binding rate (recently measured in our lab: P. Tran, unpublished data).  Although these 
effects are similar to the effects caused by β2F200A or α1R67, the effects of β2Y97A are 
not as severe.  Therefore the working model places GABA closest to β2F200 and α1R67.  
The arginine at position 104 of the GABA ρ1 subunit, which aligns with α1R67, 
was proposed to stabilize the carboxylate group of GABA in homomeric GABAA 
receptors (Harrison and Lummis, 2006).  They observed greater than a 10,000-fold shift 
in EC50 values ρ1R104 was mutated to alanine or to glutamic acid.  Also, docking 
simulations indicated that the carboxylate group of GABA was located close to ρ1R104 
(Harrison and Lummis, 2006). 
  
 
Figure 8.3  Putative GABA binding interactions
suggests the positively charged amino group of GABA interacts with the electronegative center of 
the aromatic F200 side-chain.  The negatively charged carboxy group of GABA likely interacts 
with a positively charged side-
candidate.  Additional residues may stabilize the bound GABA compound, for instance Y97 may 
participate with F200 to stabilize the amino group of GABA.
 
β2F200 is one of several aromatic residues that form the aroma
the heart of the binding pocket.  This structural motif is conserved in all cys
receptors and aromatic residues have been shown to stabilize binding of the ligand via 
cation-π interactions in nACh receptors (
glycine receptors (Pless et al., 2008), and 5
GABAA receptors, potential cation
have been examined, and of these, o
interaction (Padgett et al., 2007).  Analysis of a cation
.  The evidence presented in this 
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necessary to strengthen our interpretation that the amino end of GABA and β2F200 
directly interact.  
This model suggests a mechanism for the conformational changes that will induce 
receptor activation.  By binding to regions on both subunits, structural elements from 
both sides will be pulled slightly closer together than the unbound conformation.  GABA 
binding requires energy to overcome the activation barrier (Jones et al., 1998) and the 
energy required for binding may be because of such movements.  In turn these 
movements will propagate through the receptor and induce activation.  Countless studies 
have detailed ligand-induced structural rearrangements at the binding pocket of cys-loop 
receptors and the GABAA receptor specifically.  Comparison of crystallized AChBP 
unbound and bound to nicotinic agonists (Celie et al., 2004; Hansen et al., 2005), as well 
as changes in the pattern of fluorescence for site-specific labels in the GABAA receptor 
binding pocket support a general closure of the pocket during binding (Muroi et al., 
2006).  Agonist binding in our model is expected to displace Loops C and D as β2F200 
and α1R67, respectively, interact with GABA.  Loop A may also contract towards GABA 
if β2Y97 favorably interacts with the amino group of GABA.   
The presumed movement of Loop C has a variety of experimental evidence.  In 
crystallized AChBP structures, the agonist induced a rigid body motion of Loop C, 
closing over the binding site cavity (Hansen et al., 2005).  Using a chimera that contained 
the AChBP fused to the transmembrane domain of a 5-HT3A receptor, these structural 
changes in the AChBP were shown experimentally to be linked with receptor activation 
(Bouzat et al., 2004).  Indeed this chimera was functionally gated by acetylcholine, 
demonstrating that the agonist-induced changes in the AChBP can promote receptor 
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activation.  In the GABAA receptor, movement of Loop C during receptor activation was 
demonstrated using SCAM experiments (Wagner et al., 2001).  Furthermore, the mobility 
of loop C appears to be greater in the resting state of the GABAA receptor than in the 
activated state (Venkatachalan and Czajkowski, 2008).   
The transmission mechanism of the conformational changes, which occur at the 
binding site and are propagated over 50 Å to the channel pore where gating occurs, has 
not been elucidated.  The movements of Loop C and D, which would accompany GABA 
binding with β2F200 and α1R67, are likely to move the β-sheets towards the binding 
pocket or cause them to twist.  Movement of the β-sheets, which make up a large portion 
of the extracellular domain, may provide transduction of the binding signal to the 
interface of the extracellular and transmembrane domains, where electrostatic interactions 
between extracellular loops and the linker region of the second and third transmembrane 
have been identified as a critical structural element for the activation process (Kash et al., 
2003).  Also, these motions may be transmitted through the pre-M1 linker, which 
connects the extracellular and transmembrane domains (Lee and Sine, 2005).   
Additionally, a change in the quaternary subunit positioning may occur as GABA 
binds in a location that bridges the β and α subunits.  Rotation of the extracellular 
domains of each subunit would also allow transmission to the transmembrane domains 
(Unwin, 2005).  The importance of the quaternary subunit positioning of each interface 
was supported by the destabilizing effect of α1R120A and β2D163A.  Presumably these 
mutations disrupt an inter-subunit salt-bridge interaction, and thereby alter the subunit 
positioning at the inter-subunit interface.  Both mutations destabilize the ligand-receptor 
complex and decrease the rate of macroscopic receptor activation.  Furthermore, 
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disrupting an inter-subunit interaction at the γ(+)/β(-) was also shown to have effects that 
propagate to the GABA binding site (Goldschen-Ohm et al., 2010).  A change in the 
quaternary subunit positioning around the pentameric ion channel could explain how 
mutational effects are propagated to other interfaces. 
Subunit composition influences the GABA binding pocket 
During the course of these studies several surprising differences between αβ 
receptors and αβγ receptors were observed.  The αβ receptor consists of two α’s and three 
β’s , while the αβγ receptor replaces one of the β’s with a γ, consisting of two α’s, two 
β’s, and one γ subunit.  There is no doubt that αβ and αβγ receptors exhibit distinct 
kinetics.  Differences in EC50, single channel conductance, deactivation rates, and 
desensitization have been well documented (Haas and Macdonald, 1999; Boileau et al., 
2003).   Still, little work has focused on the potential structural differences at the   
β(+)/α(-) inter-subunit interfaces between αβ receptors and αβγ receptors. 
When α1R120 was mutated to alanine and expressed in αβ receptors, a 10-fold 
EC50 increase, 10-fold deactivation increase, and only a subtle decrease in the GABA 
binding rate was observed.  However, when in αβγ receptors, α1R120A caused a 10-fold 
decrease in the binding rate in addition to increasing the EC50 and the rate of deactivation.  
Why does α1R120A cause a nearly equal and opposite effect on unbinding and binding in 
αβγ receptors, but disproportionately alters unbinding in αβ receptors?  The five subunits 
are arranged pseudosymmetrically around the ion pore, and it is likely that the subunit 
positioning is not identical when γ versus β is incorporated.  Not only does this 
incorporation affect the γ(+)/β(-) or β(+)/β(-) interface, but it also manifests at the other 
interfaces.  The effect that the γ(+)/β(-) or β(+)/β(-) interface can have at distant 
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interfaces has been observed previously.  For example, a site-specific fluorescent study  
found different fluorescent patterns in the GABA binding pocket during receptor 
activation when examining αβ and αβγ receptors (Muroi et al., 2006).  Also, mutations at 
the γ(+)/β(-) interface have been shown to alter receptor properties directly associated 
with the β(+)/α(-) interface, such the GABA unbinding rate (Goldschen-Ohm et al., 
2010).  Differences between αβ receptors and αβγ receptors that occur at the GABA 
binding pocket will need to be defined as more detailed structural descriptions of the 
GABA binding pocket develop.  Certain side-chain interactions may be present in one 
receptor type, but not in another receptor type.  
The mutations that disrupted assembly also had unique characteristics in αβ 
receptors versus αβγ receptors.  The data were consistent with a gradual disruption by 
β2Y97A and γ2F112A, and a specific β(+)/β(-) interface disruption by β2Y157A.  
Considering that incorporation of a γ2 subunit can influence the β(+)/α(-) interface, 
alternative interpretations may exist.  In αβ receptors, β2Y157A may disrupt the β(+)/α(-) 
interface as well as the β(+)/β(-) interface.  However, incorporation of a γ2 subunit may 
alter the quaternary subunit positioning at the β(+)/α(-) interface, and mask any effect that 
β2Y157A had on assembly of the β(+)/α(-) interface in αβ receptors.  It raises questions 
about whether the results are contingent on the differences at β(+)/α(-) interface with αβ 
and αβγ receptors.  In any study, the subtle indirect effects of subunit composition can 
influence results and must be considered. 
Continued study of the GABA binding pocket 
The strength of the rapid-ligand application and electrophysiological techniques 
utilized in this dissertation lie in their ability to precisely characterize the effect each 
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mutation has on specific receptor functions (i.e. ligand binding, ligand unbinding, 
desensitization, or gating).  In order to establish the role a given residue plays in receptor 
function it is necessary to distinguish the various processes.  The techniques also allowed 
a detailed comparison of two residues, which made it possible to establish those that 
participate in similar receptor processes and made it possible to determine if two side-
chains are functionally coupled.  The GABA binding pocket has not been completely 
characterized and it would be beneficial to continue this work.  Complete microscopic 
kinetics for all of the residues that lie in the sub-region of the binding pocket near β2F200 
and α1R67 are needed to clarify which residues influence GABA binding the most.  Many 
alanine mutations investigated here proved too disruptive to complete the kinetic 
analysis.  More conservative mutations for β2Y157, β2T202, β2Y205 may be required to 
perform all of the electrophysiological experiments.   Additionally, the continued use of 
these techniques to explore interactions between pairs of side-chains will aid refinement 
of the binding pocket structure. 
Although a plethora of new information has been garnered by examining 
mutational effects on receptor kinetics, there are limitations to how accurately we can 
relate structure to function.  One concern is that the structural consequence of a given 
mutation is not always predictable.  Structural changes are not necessarily limited to just 
the side-chain being mutated, and if a mutation produces a larger disruption of an entire 
structural element or introduces new interactions, our interpretations will be confounded.  
Another challenge when relying on electrophysiology to study the GABA binding pocket 
is the inability to experimentally confirm direct interactions with a ligand.  At best we are 
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able to identify residues that fit a set of characteristics that would occur for a direct 
interaction, but unfortunately this will not rule out an indirect interaction.    
A number of alternative strategies could be employed in conjunction with our 
current methods for characterizing receptor kinetics that would further clarify how each 
residue of the binding pocket contributes to the overall structure.  In order to explore 
side-chain chemistry, unnatural amino acid substitution could be used.  In particular this 
should be used to complete analysis of β2F200 and verify if it participates in a cation-π 
interaction.  Unnatural residue substitution can also be used to explore interactions with 
the peptide backbone.  Unnatural substitution with hydroxy acids produces an ester 
backbone linkage that does not contain a hydrogen bond donating amide group 
(Gleitsman et al., 2008).  
 In order to exploit how agonists interact in the GABA binding pocket it may also 
be prudent to compare various GABA analogues that have variations in length and charge 
distribution.  Whether mutations that disrupt GABA binding differentially affect related 
analogues could be insightful.  Lastly, mutational studies could be guided by considering 
different subunit isoforms that have varying binding properties.  The use of chimeric 
subunits, which have small segments of the binding pocket replaced with the sequence of 
another isoform, could help identify the regions that contribute to differences in binding 
properties between two subunit isoforms.  A similar strategy was used by Schmeiden et 
al. (1993) to identify a specific sequence that varies in glycine receptors and GABAA 
receptors and is critical for distinguishing glycine and GABA agonists.  Continued use of 
such experiments could help identify the specific residues that are required for GABA 
binding.  
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Outside of the electrophysiology realm, the biggest breakthroughs in GABAA 
receptor structure are likely to come from crystallization experiments that actually offer 
atomic level resolution of the binding pocket architecture.  Recently, bacterial pentameric 
ligand gated ion channels were discovered and the structures of two channels were 
determined at better than 3.3 Å resolution (Hilf and Dutzler, 2008; Bocquet et al., 2009; 
Hilf and Dutzler, 2009).  Although the prokaryotic receptors have extensive sequence 
divergence from the eukaryotic LGICs, they share a conserved extracellular ligand 
binding domain and four transmembrane domains (Tasneem et al., 2005).  The two 
prokaryotic receptors represent the first complete pentameric channel complexes ever 
crystallized, a step forward from the crystallization of the soluble AChBP (Brejc et al., 
2001), or a single nACh receptor subunit (Dellisanti et al., 2007).  The newly determined 
structures confirm many of the conserved features identified in the AChBP and the single 
nACh receptor subunit, such as the extracellular domain β-sheets and the orientation of 
the transmembrane domains.  These bacterial homologues, however, are not activated by 
the same ligands as the cys-loop receptors.  Without crystallization of a GABAA receptor 
bound to GABA it will be difficult to confirm all of the interpretations spawned by 
electrophysiological studies. 
Our description of the architecture of the GABA binding pocket is continually 
improving.  By distinguishing residues that potentially mediate GABA binding from 
those that influence gating, and identifying the residues with the strongest influence on 
GABA binding we move closer to understanding how the GABAA receptor interacts with 
the agonist.  Additional structural studies in the field will hopefully provide comparison 
for our interpretations, and the structural model will be refined as information about the 
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binding pocket accumulates.  These advances shed some light onto the biomolecular 
function of the receptor, which is able to transduce the binding of a neurotransmitter to 
the gating of an ion channel.    
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